UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30,~~March 31, ~~2021~~2022


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39549

GoodRx Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	47-5104396
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

2701 Olympic Boulevard Santa Monica, CA	90404
(Address of principal executive offices)	(Zip Code)

(855) 268-2822

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Class A ~~Common Stock,~~common stock, $0.0001 par value per share

GDRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	☒	Accelerated filer	☐

Non-accelerated filer	☐	☒	Smaller reporting company	☐

Emerging growth company	☒☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August 9, 2021,~~May 3, 2022, the registrant had ~~75,429,443~~82,726,202 shares of Class A common stock, $0.0001 par value per share, and ~~320,210,544~~313,731,628 shares of Class B common stock, $0.0001 par value per share, outstanding.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, ~~(the “Securities Act”),~~ and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to statements regarding our future results of operations and financial position, industry and business trends, the impact of a grocer not accepting PBM pricing on our future results of operations, stock compensation, our stock repurchase program, business strategy, plans, market growth and our objectives for future operations.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our ability to continue to attract, acquire and retain consumers in a cost-effective manner; our reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and pricing structures; our inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infection disease, including the COVID-19 pandemic; the accuracy of our estimate of our total addressable market and other operational metrics; the development of the telehealth market; our ability to maintain and expand a network of skilled telehealth providers; risks related to negative media coverage; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform and brand; risks related to ~~our material weaknesses in our~~any failure to maintain effective internal control over ~~financial~~ﬁnancial reporting ~~and any future material weaknesses;~~; risks related to use of social media, emails, text messages and other messaging channels as part of our marketing strategy; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to information technology and cyber-security; compliance with government regulation of the internet, e-commerce and data and other regulations; our ability to utilize our net operating loss carryforwards and certain other tax attributes; ~~management’s ability to manage our transition to being a public company;~~ our ability to attract, develop, motivate and retain well-qualified employees; risks related to general economic factors, natural disasters or other unexpected events; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites; our reliance on third-party platforms to distribute our platform and offerings; our reliance on software as-a-service technologies from third parties; systems failures or other disruptions in the operations of these parties on which we depend; changes in consumer sentiment or laws, rules or regulations regarding tracking technologies and other privacy matters; the increasing focus on environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; risks related to fluctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; as well as the other important factors discussed in the ~~section~~sections entitled “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021 (“~~2020~~2021 10-K”) and this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (“SEC”). The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report on Form 10-Q, whether as a result of any new information, future events or otherwise.

~~GOODRX HOLDINGS, INC.~~

Table of Contents


		Page

PART I.	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of ~~Changes in Redeemable Convertible Preferred Stock and~~ Stockholders’ Equity ~~(Deficit)~~	3
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1714
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3323
Item 4.	Controls and Procedures	3323

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	3624
Item 1A.	Risk Factors	3624
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3624
Item 3.	Defaults Upon Senior Securities	3624
Item 4.	Mine Safety Disclosures	3625
Item 5.	Other Information	3625
Item 6.	Exhibits	3726
	Signatures	3827

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

GoodRx Holdings, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)


(in thousands, except par values)	June 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
Assets
Current assets
Cash and cash equivalents	$	894,703		$	968,691		$	845,427		$	941,109
Restricted cash		0			2,900
Accounts receivable, net		87,004			68,729			123,281			118,080
Prepaid expenses and other current assets		94,043			46,048			26,015			29,638
Total current assets		1,075,750			1,086,368			994,723			1,088,827

Property and equipment, net		22,105			23,057			22,564			21,612
Goodwill		320,196			261,116			334,642			329,696
Intangible assets, net		94,780			36,919			85,990			88,791
Capitalized software, net		31,996			19,800			52,505			44,987
Operating lease right-of-use assets		26,902			27,712			26,978			27,705
Deferred tax assets, net		12,971			13,117
Other assets		2,229			2,025			20,926			6,007
Total assets	$	1,586,929		$	1,470,114		$	1,538,328		$	1,607,625
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$	18,378		$	10,291		$	12,820		$	17,501
Accrued expenses and other current liabilities		33,759			37,692			33,812			50,732
Current portion of debt		7,029			7,029			7,029			7,029
Operating lease liabilities, current		6,325			4,539			5,703			5,851
Total current liabilities		65,491			59,551			59,364			81,113
Debt, net		657,877			659,888			654,845			655,858
Operating lease liabilities, net of current portion		32,818			33,467			32,512			33,592
Deferred tax liabilities, net								397			244
Other liabilities		6,349			5,849			4,703			5,138
Total liabilities		762,535			758,755			751,821			775,945
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value; 50,000 shares authorized and 0 shares issued and outstanding at June 30, 2021 and December 31, 2020		—			—
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 72,054 and 63,071 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively; and Class B: 1,000,000 shares authorized, 323,339 and 328,589 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		39			39
Preferred stock, $0.0001 par value; 50,000 shares authorized and 0 shares issued and outstanding at March 31, 2022 and December 31, 2021								0			0
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 82,400 and 85,028 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively; and Class B: 1,000,000 shares authorized, 313,732 and 315,534 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively								40			40
Additional paid-in capital		2,182,079			2,101,773			2,189,881			2,247,347
Accumulated deficit		(1,357,724	)		(1,390,453	)		(1,403,414	)		(1,415,707	)
Total stockholders' equity		824,394			711,359			786,507			831,680
Total liabilities and stockholders' equity	$	1,586,929		$	1,470,114		$	1,538,328		$	1,607,625

See accompanying Notes to Condensed Consolidated Financial Statements.

GoodRx Holdings, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
(in thousands, except per share amounts)	2021			2020			2021			2020			2022			2021
Revenue	$	176,635		$	123,295		$	337,066		$	256,703		$	203,329		$	160,431
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below		11,090			6,824			21,518			12,843			12,280			10,428
Product development and technology		29,567			11,962			55,727			22,287			35,042			26,160
Sales and marketing		88,381			51,920			168,075			115,082			92,950			79,694
General and administrative		39,579			6,332			83,365			12,219			31,923			43,786
Depreciation and amortization		8,369			4,521			13,730			8,866			11,373			5,361
Total costs and operating expenses		176,986			81,559			342,415			171,297			183,568			165,429
Operating (loss) income		(351	)		41,736			(5,349	)		85,406
Operating income (loss)														19,761			(4,998	)
Other expense, net:
Other income, net		0			(16	)		0			(21	)
Interest income		(13	)		(41	)		(29	)		(116	)		(52	)		(16	)
Interest expense		5,906			6,795			11,811			15,433			5,869			5,905
Total other expense, net		5,893			6,738			11,782			15,296			5,817			5,889
(Loss) income before income taxes		(6,244	)		34,998			(17,131	)		70,110
Income tax benefit (expense)		37,305			(7,661	)		49,860			(15,427	)
Income (loss) before income taxes														13,944			(10,887	)
Income tax (expense) benefit														(1,651	)		12,555
Net income	$	31,061		$	27,337		$	32,729		$	54,683		$	12,293		$	1,668
Net income attributable to common stockholders:
Basic	$	31,061		$	17,663		$	32,729		$	35,325
Diluted	$	31,061		$	17,842		$	32,729		$	35,674
Earnings per share:
Basic	$	0.08		$	0.08		$	0.08		$	0.15		$	0.03		$	0.00
Diluted	$	0.07		$	0.08		$	0.08		$	0.15		$	0.03		$	0.00
Weighted average shares used in computing earnings per share:
Basic		408,363			230,160			407,273			230,020			414,739			406,170
Diluted		428,867			236,890			429,228			236,557			427,378			429,577

Stock-based compensation included in costs and operating expenses:
Cost of revenue	$	181		$	24		$	302		$	41		$	(46	)	$	121
Product development and technology		7,987			918			16,323			1,814			7,478			8,336
Sales and marketing		5,262			608			10,520			1,478			5,394			5,258
General and administrative		27,246			571			60,057			998			17,323			32,811

See accompanying Notes to Condensed Consolidated Financial Statements.

GoodRx Holdings, Inc.

Condensed Consolidated Statements of ~~Changes in Redeemable Convertible~~

~~Preferred Stock and~~ Stockholders’ Equity ~~(Deficit)~~

(Unaudited)


	Redeemable Convertible Preferred Stock				Class A and Class B Common Stock					Additional Paid-in			Accumulated			Total Stockholders'			Class A and Class B Common Stock					Additional Paid-in			Accumulated			Total Stockholders'
(in thousands)	Shares		Amount		Shares			Amount		Capital			Deficit			Equity			Shares			Amount		Capital			Deficit			Equity
Balances at December 31, 2020		0	$	0		391,660		$	39	$	2,101,773		$	(1,390,453	)	$	711,359
Balance at December 31, 2021																				400,562		$	40	$	2,247,347		$	(1,415,707	)	$	831,680
Stock options exercised		—		—		513			0		2,680			—			2,680			749			—		3,699			—			3,699
Stock-based compensation		—		—		—			—		48,254			—			48,254			—			—		32,161			—			32,161
Vesting of restricted stock units		—		—		608			0		0			0			0			822			—		—			—			—
Common stock withheld for tax obligations and net settlement		—		—		(324	)		0		(14,902	)		0			(14,902	)
Common stock withheld related to net share settlement																				(364	)		—		(9,561	)		—			(9,561	)
Repurchases of Class A common stock																				(5,637	)		—		(83,765	)		—			(83,765	)
Net income		—		—		—			—		—			1,668			1,668			—			—		—			12,293			12,293
Balances at March 31, 2021		0	$	0		392,457		$	39	$	2,137,805		$	(1,388,785	)	$	749,059
Stock options exercised		—		—		2,609			—		13,291			—			13,291
Stock-based compensation		—		—		—			—		42,366			—			42,366
Vesting of restricted stock units		—		—		631			—		—			—			—
Common stock withheld for tax obligations and net settlement		—		—		(304	)		—		(11,383	)		—			(11,383	)
Net income		—		—		—			—		—			31,061			31,061
Balances at June 30, 2021		0	$	0		395,393		$	39	$	2,182,079		$	(1,357,724	)	$	824,394
Balance at March 31, 2022																				396,132		$	40	$	2,189,881		$	(1,403,414	)	$	786,507

See accompanying Notes to Condensed Consolidated Financial Statements.

GoodRx Holdings, Inc.

Condensed Consolidated Statements of ~~Changes in Redeemable Convertible~~

~~Preferred Stock and~~ Stockholders’ Equity ~~(Deficit)~~

(Unaudited)


	Redeemable Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Stockholders'			Class A and Class B Common Stock					Additional Paid-in			Accumulated			Total Stockholders'
(in thousands)	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit			Shares			Amount		Capital			Deficit			Equity
Balances at December 31, 2019		126,046	$	737,009		229,750	$	460	$	8,788	$	(1,096,830	)	$	(1,087,582	)
Balance at December 31, 2020																		391,660		$	39	$	2,101,773		$	(1,390,453	)	$	711,359
Stock options exercised		—		—		467		1		691		—			692			513			—		2,680			—			2,680
Stock-based compensation		—		—		—		—		2,501		—			2,501			—			—		48,254			—			48,254
Vesting of restricted stock units																		608			—		—			—			—
Common stock withheld related to net share settlement																		(324	)		—		(14,902	)		—			(14,902	)
Net income		—		—		—		—		—		27,346			27,346			—			—		—			1,668			1,668
Balances at March 31, 2020		126,046	$	737,009		230,217	$	461	$	11,980	$	(1,069,484	)	$	(1,057,043	)
Stock options exercised		—		—		222		1		530		—			531
Stock-based compensation		—		—		—		—		2,440		—			2,440
Net income		—		—		—		—		—		27,337			27,337
Balances at June 30, 2020		126,046	$	737,009		230,439	$	462	$	14,950	$	(1,042,147	)	$	(1,026,735	)
Balance at March 31, 2021																		392,457		$	39	$	2,137,805		$	(1,388,785	)	$	749,059

See accompanying Notes to Condensed Consolidated Financial Statements.

GoodRx Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Six Months Ended June 30,						Three Months Ended March 31,
(in thousands)	2021			2020			2022			2021
Cash flows from operating activities
Net income	$	32,729		$	54,683		$	12,293		$	1,668
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		13,730			8,866			11,373			5,361
Amortization of debt issuance costs		1,727			1,596			856			863
Non-cash operating lease expense		1,791			2,232			727			872
Stock-based compensation expense		87,202			4,331			30,149			46,526
Deferred income taxes		(364	)		2,292			(394	)		(227	)
Loss on abandonment of operating lease assets		780			0
Changes in operating assets and liabilities, net of effects of business acquisitions
Changes in operating assets and liabilities, net of effects of business acquisition
Accounts receivable		(12,873	)		(10,653	)		(5,198	)		(5,670	)
Prepaid expenses and other assets		(47,241	)		(3,952	)		3,616			(9,844	)
Accounts payable		4,917			753			(4,442	)		4,943
Accrued expenses and other current liabilities		(1,897	)		23,164			(17,197	)		(67	)
Operating lease liabilities		(590	)		(224	)		(1,228	)		631
Other liabilities		500			737			(435	)		429
Net cash provided by operating activities		80,411			83,825			30,120			45,485
Cash flows from investing activities
Purchase of property and equipment		(3,058	)		(1,779	)		(1,736	)		(2,715	)
Acquisitions, net of cash acquired		(125,728	)		0
Acquisition, net of cash acquired								(6,976	)		0
Capitalized software		(13,630	)		(6,540	)		(10,682	)		(6,980	)
Investment in minority equity interest								(15,007	)		0
Net cash used in investing activities		(142,416	)		(8,319	)		(34,401	)		(9,695	)
Cash flows from financing activities
Proceeds from long-term debt		0			28,000
Payments on long-term debt		(3,515	)		(3,515	)		(1,758	)		(1,757	)
Payment for contingent consideration		(832	)		0
Payment of debt issuance costs		0			(1,306	)
Repurchases of Class A common stock								(83,765	)		0
Proceeds from exercise of stock options		15,481			1,223			3,683			2,372
Proceeds from early exercise of stock options		0			667
Employee taxes paid related to net share settlement of equity awards		(26,017	)		0			(9,561	)		(14,633	)
Net cash (used in) provided by financing activities		(14,883	)		25,069
Net cash used in financing activities								(91,401	)		(14,018	)
Net change in cash, cash equivalents and restricted cash		(76,888	)		100,575			(95,682	)		21,772
Cash, cash equivalents and restricted cash
Beginning of period		971,591			26,050			941,109			971,591
End of period	$	894,703		$	126,625		$	845,427		$	993,363
Supplemental disclosure of cash flow information
Non cash investing and financing activities
Offering costs included in accounts payable and accrued expense and other current liabilities	$	0		$	736
Right-of-use assets obtained in exchange for new operating lease liabilities		471			0
Stock-based compensation included in capitalized software development costs		3,418			610
Capitalized software development costs in accounts payable and accrued expenses and other current liabilities		828			269
Purchase of property and equipment included in accounts payable and accrued expenses and other current liabilities		0			2,125
Non cash investing and financing activities:
Stock-based compensation included in capitalized software							$	2,012		$	1,728

The following table presents a reconciliation of cash, cash equivalents and restricted cash in ~~the Company’s Condensed Consolidated Balance Sheets~~our condensed consolidated balance sheets to the total of the same such amounts shown above:


	June 30,				March 31,
(in thousands)	2021		2020		2022		2021
Cash and cash equivalents	$	894,703	$	126,625	$	845,427	$	990,463
Restricted cash		0		0		0		2,900
Total cash, cash equivalents and restricted cash	$	894,703	$	126,625	$	845,427	$	993,363

See accompanying Notes to Condensed Consolidated Financial Statements.

GoodRx Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Description of Business

GoodRx Holdings, Inc. was incorporated in September 2015~~. On October 7, 2015, GoodRx Holdings, Inc. acquired~~ ~~100% of the outstanding shares of~~ and has no material assets or standalone operations other than its ownership in its consolidated subsidiaries. GoodRx, Inc. (“GoodRx”)~~. GoodRx,~~, a Delaware corporation that was initially formed in September ~~2011.~~2011, is a wholly-owned subsidiary of GoodRx Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc.

GoodRx Holdings, Inc. and its subsidiaries ~~(the “Company”~~(collectively, "we," "us" or "our") offer information and tools to help consumers compare prices and save on their prescription drug purchases. ~~The Company operates~~We operate a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through ~~GoodRx~~our codes that can be used to save money on prescriptions across the United ~~States (the “prescription offering”). The~~States. These services are free to consumers and ~~the Company~~we primarily ~~earns~~earn revenue from ~~its~~our core business from pharmacy benefit managers ~~(“PBMs”)~~ that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. ~~The Company~~We also ~~offers~~offer other healthcare products and services, including subscriptions, pharma manufacturer solutions and telehealth services.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in our annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with ~~the Company’s~~our audited consolidated financial statements for the year ended December 31, ~~2020~~2021 and the related notes, which are included in ~~the Company's~~our Annual Report on Form 10-K filed with the SEC on March ~~12, 2021.~~1, 2022 ("2021 10-K"). The December 31, ~~2020~~2021 condensed consolidated balance sheet was derived from ~~the Company’s~~our audited consolidated financial statements as of that date. The ~~Company’s~~ condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of ~~the~~our condensed consolidated financial statements. The operating results for three months ended March 31, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022.

~~The Company’s~~Our significant accounting policies are discussed in “Note 2. Summary of Significant Accounting Policies” in the notes to ~~the~~our consolidated financial statements included in ~~the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.~~our 2021 10-K. There have been no material changes in accounting policies during the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 from those disclosed in the ~~annual~~notes to our consolidated financial statements ~~for the year ended December 31, 2020 and the related notes.~~included in our 2021 10-K.

During the three and six months ended June 30, 2021 and 2020, other than net income, the Company did not have any other elements of comprehensive income or loss. The operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities ~~(“VIEs”)~~ for which ~~the Company is~~we are the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in ~~the Company’s~~our condensed consolidated financial statements from their respective dates of acquisition.

~~Consolidation of VIEs~~

~~GoodRx Care, LLC (formerly known as HeyDoctor), a wholly owned subsidiary of the Company,~~ provides management and other services to professional service corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws that restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs.

~~Revenue of the VIEs were approximately~~ 2% of the Company’s revenue for each of the three and six months ended June 30, 2021 and 2020, respectively. The net results of operations of the VIEs for the three and six months ended June 30, 2021 and 2020 were not material. The VIEs’ total assets and liabilities were each approximately 1~~% of the Company’s total assets and liabilities at June 30, 2021 and December 31, 2020, respectively.~~

~~Segment Reporting and Geographic Information~~

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of 1 operating segment. During the three and six months ended June 30, 2021 and 2020, all of the Company’s revenue was from customers located in the United States. In addition, at June 30, 2021 and December 31, 2020, all of the Company’s right-of-use assets and property and equipment was in the United States.

Use of Estimates

The preparation of the ~~Company’s~~ condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements, including the accompanying notes. ~~The Company bases its~~We base our estimates on historical factors, current circumstances, consideration of the economic impact of COVID-19 and the experience and judgment of our management. ~~The Company evaluates its~~We evaluate our estimates and assumptions on an ongoing basis. Actual results could differ materially from ~~those estimates. Significant~~these estimates, ~~reflected~~and such differences could affect the results of operations reported in ~~the condensed consolidated financial statements include revenue recognition, valuation of intangible assets and assumptions used for purposes of determining stock-based compensation.~~future periods.

Certain Risks and Concentrations

Financial instruments that potentially subject ~~the Company~~us to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. ~~The Company maintains~~

We maintain cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. ~~The Company believes~~We believe that the financial institutions that hold ~~its~~our cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. ~~The Company has~~We have not experienced any losses in such accounts.

~~The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral.~~

~~For the three months ended June 30, 2021,~~ 3 ~~customers accounted for approximately~~ 13%, 11~~% and~~ 10~~% of the Company’s revenue, respectively. For the six months ended June 30, 2021,~~ 3 ~~customers accounted for approximately~~ 13%, 12~~% and~~ 10~~% of the Company’s revenue, respectively. For the three months ended June 30, 2020,~~ 3 ~~customers accounted for approximately~~ 17%, 17~~% and~~ 11~~% of the Company's revenue, respectively. For the six months ended June 30, 2020,~~ 3 ~~customers accounted for approximately~~ 18%, 18~~% and~~ 12~~% of the Company's revenue, respectively. At June 30, 2021,~~ 0 ~~customers accounted for more than~~ 10~~% of the Company’s accounts receivable balance. At December 31, 2020,~~ 1 ~~customer accounted for~~ 12~~% of the Company’s accounts receivable balance.~~

In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though beginning in the second half of 2020 activity in the Company’s prescription offering improved. The Company’s prescription offering sequentially increased beginning in the third quarter of 2020 through the second quarter of 2021 as consumers partially resumed their interaction with the healthcare system. In addition, the Company has experienced a significant increase in demand for its telehealth offerings. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, the actions to contain the virus or treat its impact, mutations of the virus, availability and adoption of effective vaccines and how quickly and to what extent normal economic and operating conditions can resume.

In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the

~~Company’s carrying value of goodwill and other long-lived assets, valuation of intangible assets acquired in business combinations, incentive-based compensation and income taxes.~~

As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s condensed consolidated financial statements or annual consolidated financial statements in future periods.

~~Cash, Cash Equivalents and Restricted Cash~~

~~The Company considers~~ We consider all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist primarily of U.S. treasury securities money market funds held with an investment bank and cash on deposit.

~~Cash~~ equivalents, consisting of money market funds, of $~~852.5~~772.5 million and $~~932.5~~852.5 million at ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets.

~~Restricted cash~~We extend credit to our customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally do not obtain or require collateral. For the three months ended March 31, 2022, 2 customers accounted for approximately 13% and 10% of our revenue. For the three months ended March 31, 2021, 4 customers accounted for approximately 14%, 11%, 10% and 10% of our revenue. At March 31, 2022 and December 31, 2021, 0 customer accounted for more than 10% of our accounts receivable balance.

Equity Investments

We retain minority equity interests in privately-held companies without readily determinable fair values. Our ownership interests are less than 20% of the voting stock of the investees and we do not have the ability to exercise significant influence over operating and financial policies of the investees. The equity investments are accounted for under the measurement alternative in accordance with Accounting Standards Codification ("ASC") Topic 321, Investments – Equity Securities, which is cost minus impairment, if any, plus or minus changes resulting from observable price changes. Equity investments included in other assets on our accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, ~~2020 represented cash held in an escrow pursuant to terms of~~2021 were $19.0 million and $4.0 million, respectively. We did not recognize any changes resulting from observable price changes or impairment loss during the ~~Scriptcycle, LLC business combination relating to contingent consideration, see "Note 3. Business Combinations – Scriptcycle, LLC.”~~three months ended March 31, 2022.

Recent Accounting Pronouncements

As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

Recently Adopted Accounting Pronouncements

In ~~August 2018,~~October 2021, the Financial Accounting Standards Board ~~(“FASB”~~("FASB") issued Accounting Standards Update (“ASU”) ~~2018-15,~~2021-08, ~~Customer’s~~Business Combinations (Topic 805): Accounting for ~~Implementation Costs Incurred~~Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities acquired in a ~~Cloud Computing Arrangement~~business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Under current GAAP, an acquirer generally recognizes assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. This ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that ~~is a Service Contract~~.would have been recorded by the acquiree before the acquisition under ASC 606. The amendments in this ASU ~~2018-15 requires implementation costs incurred by~~do not affect the accounting for other assets or liabilities that may arise from revenue contracts with customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud-computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customeraccordance with ASC 606, such as refund liabilities, or ~~(2) for which exercise of the renewal option is controlled by the cloud service provider. This~~in a business combination, such as customer-related intangible assets and contract-based intangible assets. The new guidance ~~may be applied retrospectively or prospectively and~~ is effective for ~~fiscal years beginning after December 15, 2020,~~us for annual and interim ~~periods within annual~~ periods beginning after December 15, ~~2021. On~~ ~~January 1, 2021, the Company adopted~~2022. Early adoption of this ASU ~~2018-15~~is permitted, including adoption in an interim period. This update should be applied prospectively ~~and cloud computing implementation costs incurred~~to business combinations occurring on or after ~~January 1, 2021 are included in other assets in~~ the ~~consolidated balance sheet and are presented within operating cash flows. As of June 30, 2021, capitalized implementation costs for cloud computing arrangements were not material.~~

~~In October 2018, the FASB issued ASU 2018-17,~~ ~~Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities~~. ASU 2018-17 changes how entities evaluate decision-making fees under the variable interest entity guidance. To determine whether decision-making fees represent a variable interest, an entity considers indirect interests held through related parties under common control on a proportional basis, rather than in their entirety. This guidance is effective for fiscal years, beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, with early adoption permitted. All entities are required to apply the amendments in this ASU retrospectively with a cumulative-effect adjustment to retained earnings or accumulated deficit at the beginningdate of the ~~earliest period presented. The Company adopted this guidance on~~ ~~January 1, 2021, and the adoption did not have any impact to the Company’s consolidated financial statements.~~

~~In December 2019, the FASB issued ASU 2019-12,~~ ~~Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes~~. The objective of the guidance is to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and to provide more consistent application to improve the comparability of financial statements. The guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Companyamendments. We early adopted this guidance on January 1, ~~2021~~,2022, and the adoption did not have a material impact to ~~the Company’s consolidated financial statements.~~

~~Recently Issued Accounting Pronouncements - Not Yet Adopted~~

~~In June 2016, the FASB issued ASU 2016-13,~~ ~~Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments~~, to require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), which amends the language in Subtopic 326-20 and addresses questions primarily regarding documentation and company policies. The guidance in ASU 2016-13 and ASU 2020-02 related to credit losses is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on itsour consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. The ASU applies only to contracts, hedging relationships and other transactions that reference ~~LIBOR~~LIBO Screen Rate or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this ASU were effective upon issuance and may be applied through December 31, 2022. ~~The Company is currently evaluating the impact of~~We adopted this guidance on January 1, 2022, and the adoption ~~of this ASU on its~~did not have a material impact to our consolidated financial statements. We intend to apply this guidance for contract modifications related to the reference rate reform as they occur through December 31, 2022.

3. Business ~~Combinations~~

~~RxSaver, Inc.~~Combination

On ~~April 30, 2021, the Company~~February 18, 2022, we acquired all of the ~~outstanding~~ equity interests of ~~RxSaver,~~flipMD, Inc. ~~(“RxSaver”~~("flipMD"). Similar to the Company’s prescription offering business, RxSaver operates a price comparison platform to provide discount offerings through partnerships with PBMs. The acquisition expands the Company’s business capabilities and consumer reach, particularly with respect to its prescription offering. The aggregate purchase consideration was for $~~50.7~~7.0 million in ~~cash. The purchase consideration is~~cash, subject to ~~net working capital~~customary closing adjustments. flipMD is a marketplace connecting practicing physicians with organizations seeking on-demand medical expertise and ~~other closing adjustments.~~

~~Goodwill associated~~expands both our engagement with ~~this acquisition totaled $25.9~~ ~~million~~healthcare providers and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill is deductible for tax purposes. ~~Identifiable intangible assets related to this acquisition totaled $25.2~~ ~~million, of which $20.7~~ ~~million was attributable to a customer related intangible asset, with an estimated useful life of~~ ~~13 years; and $4.5~~ ~~million was attributable to developed technology and a tradename with estimated useful lives ranging from~~ 1 to ~~3 years. In addition, the Company acquired tangible assets of $3.6~~ ~~million, principally comprised of accounts receivable, and assumed liabilities of $4.0~~ ~~million.~~

services currently available under our existing pharma manufacturer solutions platform. Unaudited supplemental pro forma financial information and the revenue and earnings from the date of acquisition through March 31, 2022 for the ~~RxSaver~~flipMD acquisition has not been presented because the effects ~~are~~were not material to ~~the Company’s~~our condensed consolidated financial statements.

The purchase accounting for the ~~RxSaver~~flipMD acquisition remains incomplete with respect to acquired tangible and intangible assets and liabilities assumed as management continues to gather and evaluate information about circumstances that existed as of the acquisition date.incomplete. Measurement period adjustments, if any, will be recognized in the reporting period in which the adjustment amounts are determined within twelve months from the acquisition date.

~~HealthiNation Inc.~~

On ~~April 16, 2021~~, the Company acquired all of the outstanding equity interests of HealthiNation Inc. (“HealthiNation”). HealthiNation is a leading provider of engaging and informative health video content across all main categories of healthy living. The acquisition allows the Company to supplement and expand the services currently available under its existing pharma manufacturer solutions platform. The aggregate purchase consideration was $~~76.6~~ ~~million in cash. The purchase consideration is subject to net working capital and other closing adjustments.~~

~~Goodwill associated with this acquisition totaled $33.2~~ ~~million~~ and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered a stock acquisition for tax purposes and, accordingly, goodwill is not deductible for tax purposes. ~~Identifiable intangible assets related to this acquisition totaled $40.0~~ ~~million, of which $28.0~~ ~~million was attributable to a customer related intangible asset, with an estimated useful life of~~ ~~11 years; $9.5~~ ~~million was attributable to a content library with an estimated useful life of~~ ~~3 years; $1.9~~ ~~million was attributable to an order backlog, with an estimated useful life of~~ ~~1 year; and $0.6~~ ~~million was attributable to developed technology and a tradename with estimated useful lives of~~ ~~1 year. In addition, the Company acquired tangible assets of $5.0~~ ~~million, principally comprised of acquired cash and accounts receivable, and assumed liabilities of $1.6~~ ~~million.~~

Unaudited supplemental pro forma financial information for the HealthiNation acquisition has not been presented because the effects are not material to the Company’s condensed consolidated financial statements.

The purchase accounting for the HealthiNation acquisition remains incomplete with respect to acquired tangible and intangible assets and liabilities assumed as management continues to gather and evaluate information about circumstances that existed as of the acquisition date. Measurement period adjustments, if any, will be recognized in the reporting period in which the adjustment amounts are determined within twelve months from the acquisition date.

~~Scriptcycle, LLC~~

On ~~August 31, 2020~~, the Company acquired all of the equity interests of Scriptcycle, LLC (“Scriptcycle”). Scriptcycle specializes in managing prescription programs and primarily partners with regional retail pharmacy chains to provide discount offerings. The purpose of the acquisition was to help expand the Company’s business capabilities, particularly with respect to its prescription offering. The aggregate purchase consideration was $~~58.3~~ ~~million, including the estimated fair value of contingent consideration of $0.8~~ ~~million. The purchase consideration was subject to working capital and other closing adjustments. The maximum amount of contingent consideration payable was $2.9~~ ~~million subject to the achievement of certain revenue thresholds through January 2021.~~

~~As of December 31, 2020, the fair value of the contingent consideration was $2.9~~ ~~million, which represents the maximum amount of contingent consideration payable, based upon the Company’s assessment of the revenue thresholds that were achieved. The $2.9~~ ~~million contingent consideration was paid in full during the three months ended June 30, 2021.~~

~~Goodwill associated with this acquisition totaled $24.9~~ ~~million~~ ~~and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce.The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill was deductible for tax purposes.~~ ~~Identifiable intangible assets related to this acquisition totaled $28.3~~ ~~million, of which $25.3~~ ~~million was attributable to a customer related intangible asset, with an estimated useful life of~~ ~~11 years~~ ~~and $3.0~~ ~~million was attributable to developed technology and a tradename with useful lives ranging from~~ 1 to ~~9 years. In addition, the Company acquired current assets of $5.9~~ ~~million and assumed liabilities of $1.1~~ ~~million.~~

Unaudited supplemental pro forma financial information for the Scriptcycle acquisition has not been presented because the effects are not material to the Company’s condensed consolidated financial statements.

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


(in thousands)	June 30, 2021		December 31, 2020		March 31, 2022		December 31, 2021
Income taxes receivable	$	79,797	$	28,564	$	5,826	$	8,331
Prepaid expenses		14,246		17,484		20,189		21,307
Total prepaid expenses and other current assets	$	94,043	$	46,048	$	26,015	$	29,638

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:


(in thousands)	June 30, 2021		December 31, 2020		March 31, 2022		December 31, 2021
Accrued bonus and other payroll related	$	13,500	$	13,607	$	10,213	$	24,031
Accrued marketing		8,773		10,045		8,479		15,493
Deferred revenue		8,899		6,852		10,319		6,869
Other accrued expenses		2,587		7,188		4,801		4,339
Total accrued expenses and other current liabilities	$	33,759	$	37,692	$	33,812	$	50,732

~~The Company expects~~Deferred revenue represents payments received in advance of providing services for subscriptions and certain advertising contracts with customers. We expect substantially all of the deferred revenue at ~~June 30, 2021~~March 31, 2022 will be recognized as revenue within the ~~next~~subsequent twelve months. Of the $6.9 million of deferred revenue ~~included in the condensed consolidated balance sheet~~ at December 31, ~~2020,~~2021, $~~1.4~~ ~~million and $5.7~~4.5 million was recognized as revenue during the three ~~and six~~ months ended ~~June 30, 2021, respectively.~~March 31, 2022. Revenue recognized during the three ~~and six~~ months ended ~~June 30, 2020~~March 31, 2021 of $~~0.9~~4.3 million ~~and $2.8~~ ~~million, respectively,~~ was included as deferred revenue at December 31, ~~2019.~~2020.

6. Income Taxes

~~The Company calculates~~We generally calculate income taxes in interim periods by applying an estimated annual effective income tax rate to ~~(loss)~~ income or loss before income taxes and by calculating the tax effect of discrete items recognized during ~~the period.~~

~~The Company's~~such periods. Our estimated annual effective income tax rate is based on ~~its~~our estimated full year income or loss and the related income taxes for each jurisdiction in which ~~the Company operates.~~we operate. This rate can be affected by estimates of full year ~~pretax~~pre-tax income or loss and permanent differences.

The ~~Company’s interim~~effective income tax rate was 11.8% and ~~estimated annual~~115.3% for the three months ended March 31, 2022 and 2021, respectively. The primary differences between our effective income tax rates ~~differ from~~and the ~~U.S. Federal~~federal statutory tax rate of ~~21.0% primarily~~for the three months ended March 31, 2022 and 2021 were due to the effects of non-deductible officers’ stock-based compensation expense, state income taxes, ~~and~~ benefits from research and development tax ~~credits. In addition, the Company's~~credits and excess tax benefits from our equity awards. The effective income tax rate ~~includes recognized~~for the three months ended March 31, 2022 was further impacted by the valuation allowance on our net deferred tax assets.

We consider all available evidence, both positive and negative in assessing the extent to which a valuation allowance should be applied against our net deferred tax assets. Due principally to cumulative three-year pre-tax losses adjusted for permanent adjustments, primarily from substantial excess tax benefits realized from ~~its equity awards~~the exercise of stock options granted prior to our initial public offering ("IPO"), and a significant number of outstanding stock options granted prior to our IPO that are or will be available to be exercised in future tax periods which may generate incremental excess tax benefits if they are exercised, we maintain a full valuation allowance against our net deferred tax assets in excess of tax amortizable goodwill as ~~a discrete item.~~of March 31, 2022.

Our judgment regarding the need of a valuation allowance may reasonably change in the next twelve months. The exact timing and amount of any release of the valuation allowance is subject to change depending on the level of tax profitability that we achieve, changes in tax laws or regulations, and exercises of outstanding stock options granted prior to our IPO in future periods.

As of December 31, ~~2020, the Company~~2021, we had unrecognized tax benefits of $~~7.4~~14.8 ~~million.~~million, of which approximately $5.1 million of unrecognized tax benefits, if recognized, would impact the effective income tax rate. The remaining $9.7 million of unrecognized tax benefits would not impact the effective income tax rate to the extent that we continue to maintain a full valuation allowance against our net deferred tax assets. There were 0 significant changes to ~~the Company’s~~our unrecognized tax benefits during the three ~~and six~~ months ended ~~June 30, 2021,~~March 31, 2022, and ~~the Company does~~we do not expect to have any significant changes to unrecognized tax benefits through the end of ~~2021.~~2022.

7. Debt

~~The Company has~~We have a term loan with an original principal amount of $700.0 million (the “First Lien Term Loan Facility”) under ~~its~~our first lien credit agreement (the “First Lien Credit Agreement”) obtained through ~~its~~our wholly owned subsidiary GoodRx as borrower and collateralized by substantially all of ~~the~~our assets ~~of the Company~~ and 100% of the equity of GoodRx. The First Lien Term Loan Facility requires quarterly payments through September 2025, with any unpaid principal and interest due upon maturity on in October ~~10,~~ 2025,, and bears interest at a rate per annum equal to the LIBO Screen Rate plus a variable margin ~~based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement),~~ ranging from 2.75% to 3.00%. The effective interest rate on the First Lien Term Loan Facility for each of the three months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ was 3.39% ~~and~~ .~~3.83%, respectively. The effective interest rate on the First Lien Term Loan Facility for the six months ended June 30, 2021 and 2020 was~~ ~~3.39% and~~ ~~4.33%, respectively.~~

~~The Company~~We also ~~has~~have a line of credit with a maximum principal amount of $100.0 million (the “Revolving Credit Facility”) ~~associated with the First Lien Credit Agreement. The Revolving Credit Facility~~which matures on inOctober ~~11,~~ 2024 and bears interest at ~~a rate equal to the~~ LIBO Screen Rate plus ~~a variable margin based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement),~~rates ranging from 2.50% to 3.00% on used amounts and 0.25% to 0.50% on unused amounts. There ~~were~~was 0 ~~borrowings~~borrowing outstanding ~~under~~and the ~~Revolving Credit Facility as of June 30, 2021 and December 31, 2020. There were~~ outstanding letters of credit issued ~~against the Revolving Credit Facility for~~were $~~9.1~~9.2 million as of ~~June 30, 2021 and December~~March 31, ~~2020,~~2022, which reduces ~~the Company’s~~our available borrowings under the Revolving Credit Facility.

Our

~~The Company’s~~ debt consisted of the following:

(in thousands)

June 30,
2021

December 31,
2020

Principal balance under First Lien Term
Loan Facility

$
677,611

$
681,126

Less: Unamortized debt issuance costs
and discounts

(12,705
)

(14,209
)

$
664,906

$
666,917


(in thousands)	March 31, 2022			December 31, 2021
Principal balance under First Lien Term Loan Facility	$	672,339		$	674,097
Less: Unamortized debt issuance costs and discounts		(10,465	)		(11,210	)
	$	661,874		$	662,887

As of ~~June 30, 2021, the Company is~~March 31, 2022, we are subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Credit Agreement. Additionally, GoodRx is restricted from making dividend payments, loans or advances to ~~the Company.~~us. At ~~June 30, 2021, the Company was~~March 31, 2022, we were in compliance with ~~its~~our covenants.

8. Commitments and Contingencies

Aside from the below, as of ~~June 30, 2021,~~March 31, 2022, there were no material changes to ~~the Company’s~~our commitments and contingencies as disclosed in the notes to our consolidated financial statements included in ~~the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.~~

~~Purchase Commitments~~

~~The Company entered into a commercial agreement with a third-party during the quarter ended March 31,~~our 2021 ~~pursuant to which the Company committed to spend an aggregate of at least $3.0~~ ~~million by the end of the fiscal year ending December 31, 2021 on certain advertising services. As of June 30, 2021, the remaining commitment was $1.2~~ ~~million.~~

~~Leases~~

On May 27, 2021, the Company entered into a non-cancelable lease agreement with a third-party to lease additional office space that is adjacent to and expands its existing corporate headquarters in Santa Monica, California. The lease commences beginning in the year ~~2022~~ ~~and expires in the year~~ ~~2033~~ ~~with minimum lease payments expected to total approximately $41.4~~ ~~million over the term of the lease.~~10-K.

Legal Contingencies

On December 18, 2020, R. Brian Terenzini, individually and on behalf of all others similarly situated, filed a class action lawsuit against ~~the Company~~us and certain of ~~its~~our executive officers in the United States District Court for the Central District of California (Case No. 2:20-cv-11444). On January 8, 2021, Bryan Kearney, individually and on behalf of all others similarly situated, also filed a class action lawsuit against ~~the Company~~us and certain of ~~its~~our executive officers in the United States District Court for the Central District of California (Case No. 2:21-cv-00175). The plaintiffs seek compensatory damages as well as interest, fees and costs. The complaints allege violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and assert that ~~the Company~~we failed to disclose to investors that Amazon.com, Inc. was developing its own mobile and online prescription medication ordering and fulfillment service that would compete directly with ~~the Company.~~us. According to the

complaints, when Amazon announced its competitor service, ~~the Company’s~~our stock price fell, causing investor losses. Lead plaintiff applications were submitted February 16, 2021, and on April 8, 2021, the court consolidated the 2 lawsuits under the caption In re GoodRx Holdings, Inc.(Case No. 2:20-cv-11444)and appointed Betty Kalmanson, Lawrence Kalmanson, Shawn Kalmanson, and Janice Kasbaum as Lead Plaintiffs. On June 7, 2021, Lead Plaintiffs filed a consolidated complaint containing substantially similar factual allegations as the prior complaints, but adding claims under Section 11 of the Securities Act of 1933. ~~The Company~~We filed a motion to dismiss the consolidated case on August 6, 2021 and Lead Plaintiffs subsequently filed an omnibus opposition to our motion to dismiss on October 5, 2021. We subsequently filed a reply in support of notice of motion and motion to dismiss. The ~~Company believes it has~~court granted our motion to dismiss on January 2, 2022. The Lead Plaintiffs filed an amended complaint on February 7, 2022, and we filed a motion to dismiss the amended complaint on March 10, 2022. Briefing is ongoing, and the hearing on the motion to dismiss the amended complaint is set for June 6, 2022. We believe we have meritorious defenses to the claims of the plaintiffs and members of the class and ~~intends~~intend to defend ~~itself~~ourselves vigorously. This litigation is at preliminary stages, and the outcome of any complex legal proceeding is inherently unpredictable and subject to significant uncertainties. Based upon information presently known to management, the Company has not accrued a loss for this matter as a loss is not probable and reasonably estimable. While it is possible a loss may have been incurred, the Company is unable to estimate a loss or range of loss in this matter.

On April 29, 2021, ~~and~~ May 5, 2021 and September 15, 2021, Neesha Patel, ~~and~~ Wayne Geist and Alan Pinyavat, respectively, each filed a derivative lawsuit purportedly on behalf of ~~the Company~~us against certain of ~~its~~our officers and directors in the United States District Court for the Central District of California (Case No. 2:21-cv-03671, Case No. 2:21-cv-03829 and Case No. ~~2:21-cv-03829,~~1:21-cv-01309, respectively). The plaintiffs assert claims for breach of fiduciary duty and contribution under the Exchange Act. Neesha Patel asserts additional claims for

unjust enrichment and corporate ~~waste.~~waste and Alan Pinyavat asserts additional claims for unjust enrichment, abuse of control and gross mismanagement. These claims are based on allegations substantially similar to those in the class action lawsuit described above. Plaintiffs are requesting declaratory relief, money damages, restitution, and certain governance reforms. Plaintiffs did not make a pre-suit demand on ~~the Company’s board.~~our board of directors. The ~~Company intends to seek dismissal of these cases, or a stay~~derivative lawsuits are stayed pending the outcome of the class action lawsuit. ~~Any liability~~

In March 2020, we received a letter from the Federal Trade Commission ("FTC") indicating its intent to investigate our privacy and security practices to determine whether such practices comply with Section 5 of the FTC Act. In April 2020, the FTC sent an initial request for information to us regarding our sharing of data regarding individuals’ use of our website, app and services with service providers, including Google and Facebook. Since April 2020, we have timely responded to the FTC’s information requests and follow-up questions. On October 14, 2021, staff at the FTC notified us that it intends to recommend that the agency pursue an enforcement action against us and certain of our officers and employees. On January 12, 2022, staff at the FTC sent us a draft complaint and consent order. We believe we have complied with applicable regulations and that we have meritorious defenses to any claims or assertions to the contrary, and therefore intend to defend ourselves vigorously. No assurance can be given regarding the outcome of this matter. As a result of enforcements of this nature, there may be settlements, enforcement actions, or related litigation that could include monetary penalties and/or compliance requirements that may impose significant and material costs.

Based upon information presently known to our management, we have not accrued a loss for the ~~claims alleged~~matters described above as a loss is not ~~currently~~ probable and reasonably estimable. While it is reasonably possible a loss may have been incurred, we are unable to estimate a loss or range of loss ~~if any, is not reasonably estimable.~~in these matters.

The pending proceedings described above involve complex questions of fact and law and may require the expenditure of significant funds and the diversion of other resources to defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are reasonably possible.

In addition, during the normal course of business, ~~the Company~~we may become subject to, and is presently involved in, legal proceedings, claims and litigation. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated.

~~The Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its consolidated financial statements.~~

~~Indemnification~~

The Company’s amended and restated bylaws provides that it will indemnify the Company’s directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Certain of the Company’s officers and directors are also a party to indemnification agreements with the Company. Pursuant to the Company’s indemnification agreements and directors’ and officers’ liability insurance, certain of the Company’s officers and directors will be indemnified and insured against the cost of defense, settlement or payment of a judgment under certain circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is indeterminable. The Company has never paid a material claim, nor has the Company been involved in litigation, with respect to these indemnification arrangements. As of June 30, 2021 and December 31, 2020, the Company has not accrued a liability for these guarantees as, the likelihood of incurring a payment obligation, if any, in connection with these guarantees is not probable or reasonably estimable.10

9. Revenue

Revenue consisted of the following:

Three Months Ended
June 30,

Six Months Ended
June 30,

(in thousands)

2021

2020

2021

2020

Prescription transactions revenue

$
144,857

$
109,548

$
278,918

$
232,565

Subscription revenue (1)

14,316

6,358

26,323

11,998

Other revenue

17,462

7,389

31,825

12,140

Total revenue

$
176,635

$
123,295

$
337,066

$
256,703

(1) Represents revenue from the Company's Gold and Kroger Savings subscription offerings. Subscription revenue is disclosed separately from other revenue beginning in the second quarter of 2021. Prior period amounts have been recast to conform with the current period presentation.


	Three Months Ended March 31,
(in thousands)	2022		2021
Prescription transactions revenue	$	155,507	$	134,061
Subscription revenue (1)		19,110		12,007
Pharma manufacturer solutions revenue (2)		23,469		9,369
Other revenue		5,243		4,994
Total revenue	$	203,329	$	160,431

(1)

Represents revenue from our Gold and Kroger Savings subscription offerings. Subscription revenue is disclosed separately from other revenue beginning in the second quarter of 2021. Prior period amounts have been recast to conform with the current period presentation.

(2)

Represents revenue from pharma manufacturers and other customers for advertising, including integrating onto our platform their affordability solutions to our consumers. Pharma manufacturer solutions revenue is disclosed separately from other revenue beginning in the first quarter of 2022. Prior period amounts have been recast to conform with the current period presentation.

10. Stockholders' Equity

On February 23, 2022, our board of directors authorized the repurchase of up to an aggregate of $250.0 million of our Class A common stock through February 23, 2024 (the "repurchase program"). Repurchases under the repurchase program may be made in the open market, in privately negotiated transactions or otherwise, with the amount and timing of repurchases to be determined at our discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. We may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of our shares under this authorization. This repurchase program does not obligate us to acquire any particular amount of Class A common stock and may be modified, suspended or terminated at any time at the discretion of our board of directors.

During the three months ended March 31, 2022, we repurchased and retired 5.6 million shares of our Class A common stock for an aggregate purchase price of $83.8 million under the repurchase program. We had $166.2 million available for future repurchases of our Class A common stock under the repurchase program as of March 31, 2022.

11. Stock-Based Compensation

Stock Options

A summary of the stock option activity is as follows:

Weighted

Weighted

Average

Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

(in thousands, except per share amounts and term information)

Shares

Price

Term

Value

Outstanding at December 31, 2020

21,528

$
6.22

Granted

0

0

Exercised

(513
)

5.23

Expired / Cancelled / Forfeited

(253
)

6.07

Outstanding at March 31, 2021

20,762

$
6.24

7.9 years

$
680,528

Granted

0

0

Exercised

(2,609
)

5.09

Expired / Cancelled / Forfeited

(222
)

7.71

Outstanding at June 30, 2021

17,931

$
6.39

7.7 years

$
531,079

Exercisable at June 30, 2021

8,756

$
4.36

6.8 years

$
277,143


						Weighted
				Weighted		Average
				Average		Remaining	Aggregate
				Exercise		Contractual	Intrinsic
(in thousands, except per share amounts and term information)	Shares			Price		Term	Value
Outstanding at December 31, 2021		13,568		$	7.55	7.3 years	$	341,929
Granted		1,163			17.17
Exercised		(749	)		4.94
Expired / Cancelled / Forfeited		(281	)		16.80
Outstanding at March 31, 2022		13,701		$	8.32	7.0 years	$	165,307
Exercisable at March 31, 2022		7,139		$	5.80	6.0 years	$	101,277

~~There were~~

011

~~stock options granted during the three and six months ended June 30, 2021.~~

The weighted-average grant date fair value per share of stock options granted for the three ~~and six~~ months ended ~~June 30, 2020~~March 31, 2022 was $~~3.17~~10.92 ~~and $3.04, respectively. The aggregate intrinsic value of options exercised for the three months ended June 30, 2021 and 2020 was $79.9~~ ~~million and $1.0~~ ~~million, respectively. The aggregate intrinsic value of options exercised for the six months ended June 30, 2021 and 2020 was $98.6~~ ~~million and $2.4~~ ~~million, respectively.~~

All options outstanding at June 30, 2021 are options to purchase shares of Class A common stock. The fair value of option awards issued with service or service and performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The Company does not have material stock options issued with market vesting conditions.

For the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ the stock-based compensation expense related to stock options was $~~3.9~~2.0 million and $~~1.7~~ ~~million, respectively. For the six months ended June 30, 2021 and 2020, the stock-based compensation expense related to stock options was $8.1~~ ~~million and $3.4~~4.2 million, respectively. At ~~June 30, 2021,~~March 31, 2022, there was $~~26.5~~31.7 million of total unrecognized stock-based compensation cost related to stock options, which is expected to be recognized over a weighted average remaining service period of ~~2.5~~2.0 years.

Restricted Stock Awards and Restricted Stock Units

A summary of the Restricted Stock Awards ~~(“RSAs”)~~ and Restricted Stock ~~Unit~~Units (“RSUs”) activity is as follows:

Restricted

Restricted
Stock Units
for Class A

Restricted
Stock Units
for Class B

Weighted
Average

Stock

Common

Common

Grant Date

(in thousands, except per share amounts)

Awards

Stock

Stock

Fair Value

Nonvested restricted stock awards or restricted
   stock units at December 31, 2020

1,409

2,790

7,698

$
26.74

Granted

0

647

0

44.12

Vested

0

(95
)

(513
)

29.12

Forfeited

0

(17
)

0

42.31

Nonvested restricted stock awards or restricted
   stock units at March 31, 2021

1,409

3,325

7,185

$
28.05

Granted

0

618

0

37.86

Vested

(470
)

(118
)

(513
)

18.68

Forfeited

0

(67
)

0

36.61

Nonvested restricted stock awards or restricted
   stock units at June 30, 2021

939

3,758

6,672

$
29.44


	Restricted		Restricted Stock Units for Class A			Restricted Stock Units for Class B			Weighted Average
	Stock		Common			Common			Grant Date
(in thousands, except per share amounts)	Awards		Stock			Stock			Fair Value
Nonvested restricted stock awards or restricted stock units at December 31, 2021		939		4,431			5,645		$	29.64
Granted		0		2,283			0			17.88
Vested		0		(309	)		(513	)		31.83
Forfeited		0		(201	)		0			38.32
Nonvested restricted stock awards or restricted stock units at March 31, 2022		939		6,204			5,132		$	27.15

~~There were~~ 0 ~~RSUs granted or outstanding during the three and six months ended June 30, 2020.~~

~~Restricted Stock Awards~~

~~For the three months ended June 30, 2021 and 2020, total stock-based compensation expense related to RSAs was $0.5~~ ~~million and $0.4~~ ~~million, respectively. For the six months ended June 30, 2021 and 2020, total stock-based compensation expense related to RSAs was $1.0~~ ~~million and $0.9~~ ~~million, respectively. At June 30, 2021, there was $3.2~~ ~~million of total unrecognized stock-based compensation cost related to these RSAs which is expected to be recognized over the remaining service period of~~ ~~1.8~~ ~~years. There were~~ 0 ~~RSAs granted subsequent to December 31, 2019.~~

Restricted Stock Units for Class A Common Stock

For the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, ~~total~~the stock-based compensation expense related to RSUs for Class A common stock was $~~12.3~~13.8 million and $~~24.1~~11.8 million, respectively. At ~~June 30, 2021,~~March 31, 2022, there was $~~131.7~~166.2 million of total unrecognized stock-based compensation cost related to these RSUs, which is expected to be recognized over ~~the~~a weighted average remaining service period of ~~3.4~~3.0 years.

Restricted Stock Units for Class B Common Stock

OnIn September ~~11,~~ 2020, ~~the~~our board of directors granted RSUs covering an aggregate of ~~24,633,066~~24.6 million shares of Class B common stock to ~~the Company’s~~our Co-Chief Executive Officers (the “Founders Awards”), subject to the completion of our IPO and continued employment through the ~~Company’s initial public offering.~~applicable vesting dates. Each of ~~the~~our Co-Chief Executive Officers received (i) ~~8,211,022~~8.2 million RSUs that vest based on the achievement of certain stock price goals ~~ranging from $6.07~~ ~~per share to $51.28~~ ~~per share, subject to continued employment through the applicable vesting date~~ (the “Performance-Vesting Founders Awards”) and (ii) ~~4,105,511~~4.1 million RSUs that vest and settle in equal quarterly installments over four years, subject to ~~continued employment through the applicable~~certain vesting ~~date~~acceleration terms (the “Time-Vesting Founders Awards”). The grant date fair value of these awards was $533.3 million. ~~The Performance-Vesting Founders Awards vested during the fourth quarter~~All of 2020 and will be settled in shares of common stock in October 2023 or, if earlier, upon a qualifying change in control event or to satisfy tax withholding requirements. The Time-Vesting Founders Awards are subject to vesting acceleration terms upon a qualifying change in control. All the stock price goals with respect to the Performance-Vesting Founders Awards were achieved as of October 22, 2020. As a result, all ~~16,422,044~~ ~~Performance-Vesting Founders Awards vested during the year ended December 31, 2020. As of June 30, 2021, the Company has recognized a cumulative $427.0~~ ~~million of stock-based compensation expense related to the Founders Awards, of which $107.2~~ ~~million related to the Time-Vesting Founders Awards and $319.8~~ million related to the Performance-Vesting Founders Awards. During the three and six months ended June 30, 2021, the Company recognized stock-based compensation expense related to the Time-Vesting Founders Awards of $~~24.0~~ ~~million and $54.0~~ ~~million, respectively. At June 30, 2021, there was $106.3~~ ~~million of total unrecognized stock-based compensation cost related to the Time-Vesting Founders Awards, which is expected to be recognized over the weighted average remaining service period of~~ ~~1.9~~ ~~years. The Company expects to recognize a total of $36.9~~ ~~million in stock-based compensation expense related to the Time-Vesting Founders Awards in the second half of 2021.~~

As the Performance-Vesting Founders Awards vested in ~~October~~ 2020 ~~the Company~~and we settled 0.7 million RSUs ~~during the fourth quarter of 2020,~~at that time sufficient to satisfy ~~FICA~~certain tax withholding obligations due in the year of vesting. The remaining 15.7 million Performance-Vesting Founders Awards shares will not be ~~issued~~settled until October 2023 or, if earlier, upon a change in control event, as defined in the RSU agreements governing the Founders Awards.

For the three months ended March 31, 2022 and 2021, the stock-based compensation expense related to the Time-Vesting Founders Awards was $13.9 million and $30.0 million, respectively. At March 31, 2022, there was $55.5 million of total unrecognized stock-based compensation cost related to the Time-Vesting Founders Awards, which is expected to be recognized over a weighted average remaining service period of 1.3 years.

~~11.~~12. Basic and Diluted Earnings Per Share

The computation of earnings per share for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ is as follows:


	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended March 31,
(in thousands, except per share amounts)	2021		2020			2021		2020			2022		2021
Numerator:
Net income	$	31,061	$	27,337		$	32,729	$	54,683		$	12,293	$	1,668
Less: Undistributed earnings allocated to convertible preferred stock		0		(9,674	)		0		(19,358	)
Net income attributable to common stockholders - basic	$	31,061	$	17,663		$	32,729	$	35,325
Add: Undistributed earnings reallocated to holders of common stock		0		179			0	349
Net income attributable to common stockholders - diluted	$	31,061	$	17,842		$	32,729	$	35,674
Denominator:
Weighted average shares - basic		408,363		230,160			407,273		230,020			414,739		406,170
Dilutive impact of stock options, restricted stock awards and restricted stock units		20,504		6,730			21,955		6,537			12,639		23,407
Weighted average shares - diluted		428,867		236,890			429,228		236,557			427,378		429,577
Earnings per share:
Basic	$	0.08	$	0.08		$	0.08	$	0.15		$	0.03	$	0.00
Diluted	$	0.07	$	0.08		$	0.08	$	0.15		$	0.03	$	0.00

The following weighted average potentially dilutive shares were excluded from the computation of diluted earnings per share for the periods presented because including them would have been antidilutive:

Three Months Ended
June 30,

Six Months Ended
June 30,

(in thousands)

2021

2020

2021

2020

Redeemable convertible preferred stock

0

126,046

0

126,046

Stock options, restricted stock awards and restricted
stock units

3,277

11,556

1,904

11,309


	Three Months Ended March 31,
(in thousands)	2022		2021
Stock options and restricted stock units		4,902		531

~~12.~~13. Subsequent ~~Events~~Event

On ~~July 7, 2021, the Company~~April 14, 2022, we acquired ~~substantially~~ all of the ~~assets~~equity interests of ~~RxNXT LLC~~vitaCare Prescription Services, Inc. (“~~RxNXT”~~vitaCare”), a wholly-owned subsidiary of TherapeuticsMD, Inc., for $~~14.5~~150.0 million in cash ~~subject~~paid at closing and contingent consideration of up to ~~customary closing adjustments. RxNXT~~$7.0 million payable in cash based upon its achievement of certain specified revenue results through 2023. We also established a management incentive plan under which certain continuing vitaCare employees would be eligible to receive up to $10.0 million of additional compensation upon achievement of certain performance milestones. vitaCare is a prescription technology ~~platform.~~and service platform that simplifies the prescription fulfillment process for consumers taking brand medications by helping them gain access to therapies and stay on those therapies for as long as medically appropriate. The purpose of the acquisition is to ~~help~~strengthen and expand ~~the Company’s business capabilities, particularly with respect to its prescription offering.~~ services currently available under our existing pharma manufacturer solutions platform.

The acquisition will be accounted for as a business combination under ~~Accounting Standard Codification~~ASC 805, Business ~~Combinations~~Combinations. ~~, using the acquisition method of accounting, which among other things, requires the acquired assets and assumed liabilities be recorded at their fair values.~~ The determination of the fair values of the acquired assets and assumed liabilities is incomplete due to the recent date of the acquisition. ~~The results of operations of RxNXT will be included in the consolidated results of the Company beginning from the date of acquisition.~~

~~On July 21, 2021, the Company’s board of directors granted equity awards to certain employees comprised principally of RSUs for~~ ~~0.5~~ ~~million shares of Class A common stock, which will substantially vest over a~~ ~~four-year~~ ~~period. The Company estimates the grant date fair value of these RSUs is approximately $15.2~~ ~~million, which will be recognized as stock-based compensation cost, net of forfeitures that occur, over approximately~~ ~~four years~~.

1613

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and Part II, Item 8, “Financial Statements and Supplementary Data” included in our ~~2020~~Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 10-K") filed with the SEC on March ~~12, 2021.~~1, 2022. This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the "Risk Factors" section of our ~~2020~~2021 10-K ~~and this Quarterly Report on Form 10-Q~~ and other factors set forth in other parts of this Quarterly Report on Form 10-Q and our filings with the SEC.

Glossary of Selected Terminology

As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires, references to:

•

“we,” “us,” “our,” the “Company,” “GoodRx,” and similar references refer to GoodRx Holdings, Inc. and its consolidated subsidiaries.



“~~Co-Founders~~” ~~refers to Trevor Bezdek and Douglas Hirsch, our Co-Chief Executive Officers and members of our board of directors.~~

•

“consumers” refer to the general population in the United States that uses or otherwise purchases healthcare products and services. References to “our consumers” or “GoodRx consumers” refer to consumers that have used one or more of our offerings.

•

“discounted price” refers to a price for a prescription provided on our platform that represents a negotiated rate provided by one of our PBM partners at a retail pharmacy. Through our platform, our discounted prices are free to access for consumers by saving a GoodRx code to their mobile device for their selected prescription and presenting it at the chosen pharmacy. The term “discounted price” excludes prices we may otherwise source, such as prices from patient assistance programs for low-income individuals and Medicare prices, and any negotiated rates offered through our subscription offerings: GoodRx Gold (“Gold”), and Kroger Rx Savings Club powered by GoodRx (“Kroger Savings”).

•

“GoodRx code” refers to codes that can be accessed by our consumers through our apps or websites or that can be provided to our consumers directly by healthcare professionals, including physicians and pharmacists, that allow our consumers free access to our discounted prices or a lower list price for their prescriptions when such code is presented at their chosen pharmacy.

•

“Monthly Active Consumers” refers to the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who used our telehealth offerings. When presented for a period longer than a month, Monthly Active Consumers is averaged over the number of calendar months in such period. For example, a unique consumer who uses a GoodRx code twice in January, but who did not use our prescription transactions offering again in February or March, is counted as 1 in January and as 0 in both February and March, thus contributing 0.33 to our Monthly Active Consumers for such quarter (average of 1, 0 and 0). A unique consumer who uses a GoodRx code in January and in March, but did not use our prescription transactions offering in February, would be counted as 1 in January, 0 in February and 1 in March, thus contributing 0.66 to our Monthly Active Consumers for such quarter. Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition.

•

“PBM” refers to a pharmacy benefit manager. PBMs aggregate demand to negotiate prescription medication prices with pharmacies and pharma manufacturers. PBMs find most of their demand through relationships with insurance companies and employers. However, nearly all PBMs also have consumer direct or cash network pricing that they negotiate with pharmacies for consumers who choose to purchase prescriptions outside of insurance.

•

“pharma” is an abbreviation for pharmaceutical.

•

“savings,” “saved” and similar references refer to the difference between the list price for a particular prescription at a particular pharmacy and the price paid by the GoodRx consumer for that prescription utilizing a GoodRx code available through our platform at that same pharmacy. In certain circumstances, we may show a list price on our platform when such list price is lower than the negotiated price available using a GoodRx code and, in certain circumstances, a consumer may use a GoodRx code and pay the list price at a pharmacy if such list price is lower than the negotiated price available using a GoodRx code. We do not earn revenue from such transactions, but our savings calculation includes an estimate of the savings achieved by the consumer because our platform has directed the consumer to the pharmacy with the low list price. This estimate of savings when the consumer pays the list price is based on internal data and is calculated as the difference between the average list price across all pharmacies where GoodRx consumers paid the list price and the average list price paid by consumers in the pharmacies to which we directed them. We do not calculate savings based on insurance prices as we do not have information about a consumer’s specific coverage or price. We do not believe savings are representative or indicative of our revenue or results of operations.

•

“subscribers” and similar references refers to our consumers that are subscribed to either of our subscription ~~plans, GoodRx~~offerings, Gold or Kroger ~~Savings Club.~~



“~~Silver Lake Partners~~” ~~refers~~Savings. References to ~~investment funds associated with Silver Lake Partners, including SLP Geology Aggregator, L.P.~~subscription plans as of a particular date represents an active subscription to either one of our aforementioned subscription offerings as of the specified date. Each subscription plan may represent more than one subscriber since family subscription plans may include multiple members.

Certain monetary amounts, percentages, and other figures included in this Quarterly Report on Form 10-Q have been subject to rounding adjustments. Percentage amounts included in this Quarterly Report on Form 10-Q have not in all cases been calculated on the basis of such rounded figures, but on the basis of such amounts prior to rounding. For this reason, percentage amounts in this Quarterly Report on Form 10-Q may vary from those obtained by performing the same calculations using the figures in our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Certain other amounts that appear in this Quarterly Report on Form 10-Q may not sum due to rounding.

Overview

Our mission is to help Americans get the healthcare they need at a price they can afford. To achieve this, we are building the leading, consumer-focused digital healthcare platform in the United States.

Healthcare consumers in the United States face an increasing number of challenges. These include a lack of affordability, transparency, and access to care. Additionally, healthcare professionals’ lack of access to current prescription pricing and out of pocket consumer cost information exacerbate the challenges that healthcare consumers face. GoodRx was founded to solve these challenges. We started with a price comparison tool for prescriptions, offering consumers free access to lower prices on their medication, and have been able to deliver consumers significant value. Based on a study we conducted in June 2021, consumers of our prescription offering saved an average of 79% off retail prices on prescription medication during the year 2020. In that same year, for the 100 most purchased medications, we beat the average commercial insurance copay 55% of the time (89% of the time when ignoring geographic proximity and convenience considerations), and consumers who paid less than the average commercial insurance copay saved on average 52% off the average copays. Today, our expanded platform also provides access to brand medication savings programs, affordable and convenient medical provider consultations and lab tests via our telehealth offerings, GoodRx Care and the GoodRx Telehealth Marketplace, and other healthcare and wellness related content. Whether a consumer is insured or uninsured, young or old, or suffers from an acute or a chronic ailment, we strive to be at the consumer’s side throughout their healthcare journey. We believe that our offerings provide significant savings to consumers, and can help drive greater medication adherence, faster treatment and better patient outcomes that also benefit the broader healthcare ecosystem and its stakeholders. These all contribute to a healthier, happier society.

We believe our financial results reflect the significant market demand for our offerings and the value that we provide to the broader healthcare ecosystem. ~~Our revenue grew 43% in~~For the three months ended ~~June 30, 2021~~March 31, 2022 as compared to ~~$176.6~~the same period of 2021:

•

Revenue grew 27% to $203.3 million from $160.4 million.

•

Net income and net income margin was $12.3 million and 6.0%, respectively, up from ~~$123.3~~$1.7 million ~~in the three months ended June 30, 2020,~~ and ~~grew 31%~~1.0%, respectively. The increases in ~~the six months ended June 30, 2021 to $337.1 million, up from $256.7 million in the six months ended June 30, 2020. In the three months ended June 30, 2021,~~ net income ~~grew 14% to $31.1 million, from~~and net income ~~of $27.3 million in~~margin were principally from the three months ended June 30, 2020, and declined 40% to $32.7 million in the six months ended June 30, 2021, from $54.7 million in the six months ended June 30, 2020. Net income in the three and six months ended June 30, 2021 was impacted by $40.7 million and $87.2 million of stock-based compensation expense, respectively, which includes $24.0 million and $54.0 million of stock-based compensation expense, respectively, related to equity awards made to the Co-Chief Executive Officers in connection with the initial public offering ("IPO"). Net income for the respective periods were also impacted by $37.3 million and $49.9 million of income tax benefit, respectively, primarily due to the pre-tax losses in addition to the tax effects of nondeductible officers’ stock-based compensation expense and excess tax benefits related to our equity awards. Adjusted EBITDA grew 11% to $54.6 million in the three months ended June 30, 2021, from $49.4 million in the three months ended June 30, 2020, and grew 4% to $105.6 million in the six months ended June 30, 2021, from $101.2 million in the six months ended June 30, 2020. The continued growth of our business ~~was~~as well as a $16.4 million decrease in stock-based compensation expense primarily related to the Founders Awards (as defined and described in Note 11 to our condensed consolidated financial statements) made in connection with our initial public offering (“IPO”), partially offset by an increase to our provision for income taxes, which was a $1.7 million expense in the first quarter of 2022 and a $12.6 million benefit in the comparable period of the prior year.

•

Adjusted EBITDA was $64.7 million up from $51.0 million principally from the continued growth of our business. Adjusted EBITDA Margin was 31.8% for the three months ended March 31, 2022, unchanged from the comparable period last year. Adjusted EBITDA Margin remained flat as, relative to revenue, our reduction in sales and marketing was offset by increases in continued investments in product development and technology, ~~and sales and marketing spend, an increase in cost of revenue relative to revenue due primarily to growth of our telehealth offering,~~ as well as continued investments in our general and administrative infrastructure, ~~as we started~~particularly in relation to operating as a public company.

Adjusted EBITDA ~~is a~~and Adjusted EBITDA Margin are non-GAAP financial ~~measure.~~measures. For a reconciliation and presentation of Adjusted EBITDA and Adjusted EBITDA Margin to ~~the~~their most directly comparable GAAP financial ~~measure,~~measures, information about why we consider Adjusted EBITDA and Adjusted EBITDA Margin useful to investors and a discussion of the material risks and limitations of these measures, please see “Key Financial and Operating ~~Metrics”~~Metrics—Non-GAAP Financial Measures" below.

We have been focused on capital efficiency and delivering on a cash generative monetization model since inception. Cash flow provided by operating activities was $80.4 million in the six months ended June 30, 2021, compared to $83.8 million in the six months ended June 30, 2020.

We believe that our performance and future success depend on a number of factors that present significant opportunities for us but also pose risks and challenges. For discussion of these factors, please see our 2020 10-K and this Quarterly Report on Form 10-Q under the sections titled “Risk Factors."

On September 25, 2020, we completed our IPO by issuing 28,615,034 shares of our Class A common stock at a price to the public of $33.00 per share, resulting in net proceeds to us of $886.9 million, after deducting the underwriting discount of $52.5 million and offering expenses of $4.9 million. Additionally, certain existing stockholders sold an aggregate of 11,192,657 shares. On September 25, 2020, we also completed the sale of 3,030,303 shares of our Class A common stock at a purchase price of $33 per share to SLP Geology Aggregator, L.P., resulting in proceeds to us of $100.0 million. SLP Geology Aggregator, L.P. is an investment fund associated with Silver Lake Partners.

Impact of COVID-19

We continue to closely monitor how the spread of COVID-19 is affecting our employees, customers and business operations. The number of Monthly Active Consumers decreased and our prescription offering experienced a decline in activity in the second quarter of 2020 as compared to the first quarter of 2020 as many consumers avoided visiting healthcare professionals and pharmacies in-person, which we believe has had a similar effect across the industry. The number of Monthly Active Consumers then sequentially increased beginning in the third quarter of 2020 and through the second quarter of 2021 as consumers partially resumed their interaction with the healthcare system. Even though we saw improved activity in our prescription offering, we believe COVID-19 continues to have an adverse impact on the growth of our prescription ~~offerings~~transactions offering due to the cumulative impact of lower healthcare utilization for approximately two years since the pandemic began, and continued improvement in future periods remains uncertain. Any decrease in the number of consumers seeking to fill

prescriptions could negatively impact demand for and use of certain of our offerings, particularly our prescription ~~offering,~~transactions and subscription offerings, which would have an adverse effect on our business, financial condition and results of operations.

Conversely, pandemics, epidemics and outbreaks may significantly and temporarily increase demand for our telehealth offerings. COVID-19 has significantly accelerated the awareness and use of our telehealth offerings. While we have experienced a significant increase in demand for the telehealth offerings, there can be no assurance that the levels of interest, demand and use of our telehealth offerings will continue at current levels or will not decrease during or after the pandemic. Any such decrease could have an adverse effect on our growth and the success of our telehealth offerings.

Additionally, while the potential economic impact brought by, and the duration of any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity.

The full extent to which the outbreak of COVID-19 will continue to impact our business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, new variants of the virus, availability and adoption of effective vaccines, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the outbreak of COVID-19 has subsided, we may experience materially adverse impacts to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future.

Seasonality

We typically experience stronger consumer demand during the first and fourth quarters of each year, which coincide with generally higher consumer healthcare spending, doctor office visits, annual benefit enrollment season, and seasonal cold and flu trends. In addition, we may experience stronger demand for our pharma manufacturer solutions offering during the fourth quarter of each year, which coincides with pharma manufacturers' annual budgetary spending patterns. This seasonality may impact revenue and sales and marketing expense. The rapid growth of our business may have masked the extent of these trends to date, and we expect the impact of seasonality to be more pronounced in the future. In 2020 and 2021, we ~~have seen~~saw the impact of ~~the~~ COVID-19 pandemic further disrupt these trends, which may continue in future periods.

Recent ~~Developments~~Development

~~On July 7, 2021,~~In April 2022, we acquired ~~substantially all of the assets of RxNXT LLC (“RxNXT”~~vitaCare, Inc. ("vitaCare") ~~for $14.5 million in cash, subject~~. Refer to ~~customary closing adjustments. RxNXT is a prescription technology platform. The purpose of the acquisition is to help expand our business capabilities, particularly with respect~~Note 13 to our ~~prescription offering.~~

~~The results of operations of RxNXT will be~~condensed consolidated financial statements included elsewhere in ~~our consolidated results beginning from the date of acquisition.~~

this Quarterly Report on Form 10-Q.

Key Financial and Operating ~~Metri~~csMetrics

We use Monthly Active Consumers, subscription plans, Adjusted EBITDA and ~~Subscribers~~

Adjusted EBITDA Margin to assess our performance, make strategic and offering decisions and build our financial projections. The ~~numbers~~number of Monthly Active Consumers and ~~subscribers~~subscription plans are key indicators of the scale of our consumer base and a gauge for our marketing and engagement efforts. We believe these operating metrics reflect our scale, growth and engagement with consumers. ~~Beginning in the fourth quarter of 2020, our~~

Monthly Active Consumers ~~number~~

Our Monthly Active Consumers includes consumers we acquired through the acquisition of ~~Scriptcycle~~RxSaver, Inc. (acquired in ~~August 2020.~~April 2021) beginning in the third quarter of 2021. RxSaver, Inc. Monthly Active Consumers are estimated due to incomplete consumer information.

Three Months Ended

June 30,

March 31,

December 31,

September 30,

June 30,

2021

2021

2020

2020

2020

(in millions)

Monthly Active Consumers

6.0

5.7

5.6

4.9

4.4


	Three Months Ended
	March 31,		December 31,		September 30,		June 30,		March 31,
(in millions)	2022		2021		2021		2021		2021
Monthly Active Consumers		6.4		6.4		6.4		6.0		5.7

~~The number of Monthly Active Consumers grew in the three months ended June 30, 2021 to 6.0 million, compared to 4.4 million in the three months ended June 30, 2020.~~Subscription Plans

As of

June 30,

March 31,

December 31,

September 30,

June 30,

2021

2021

2020

2020

2020

(in millions)

Subscribers

1.1

0.9

0.8

0.7

0.6


	As of
	March 31,		December 31,		September 30,		June 30,		March 31,
(in thousands)	2022		2021		2021		2021		2021
Subscription plans		1,203		1,210		1,129		1,051		931

~~The number of subscribers grew to 1.1 million as of June 30, 2021, compared to 0.6 million as of June 30, 2020.~~

~~Adjusted EBITDA~~Non-GAAP Financial Measures

Adjusted EBITDA ~~is a~~and Adjusted EBITDA Margin are key ~~measure~~measures we use to assess our financial performance and isare also used for internal planning and forecasting purposes. We believe Adjusted EBITDA is helpful to investors, analysts and other interested parties because itthey can assist in providing a more consistent and comparable overview of our operations across our historical financial periods. In addition, ~~this measure is~~these measures are frequently used by analysts, investors and other interested parties to evaluate and assess performance.

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted, as applicable for the periods presented, for acquisition related expenses, cash bonuses to vested option holders, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on abandonment and impairment of operating lease assets, restructuring related expenses, charitable stock donation, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of revenue.

Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures and are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain expenses

that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented in this Quarterly Report on Form 10-Q, limiting their usefulness as comparative measures.

The following table presents a reconciliation of ~~Adjusted EBITDA to~~ net income, the most directly comparable financial measure calculated in accordance with ~~GAAP:~~GAAP, to Adjusted EBITDA, and presents net income margin, the most directly comparable financial measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2021			2020			2021			2020
	(dollars in thousands)
(dollars in thousands)													2022			2021
Net income	$	31,061		$	27,337		$	32,729		$	54,683		$	12,293		$	1,668
Adjusted to exclude the following:
Interest income		(13	)		(41	)		(29	)		(116	)		(52	)		(16	)
Interest expense		5,906			6,795			11,811			15,433			5,869			5,905
Income tax (benefit) expense		(37,305	)		7,661			(49,860	)		15,427
Income tax expense (benefit)														1,651			(12,555	)
Depreciation and amortization		8,369			4,521			13,730			8,866			11,373			5,361
Other income, net		—			(16	)		—			(21	)
Financing related expenses (1)		58			188			315			1,306			4			257
Acquisition related expenses (2)		3,022			780			6,070			1,243			1,973			3,048
Stock-based compensation expense (3)		40,676			2,121			87,202			4,331
Restructuring related expenses (3)														311			—
Stock-based compensation expense														30,149			46,526
Payroll tax expense related to stock-based compensation		2,016			22			2,844			81			1,083			828
Loss on abandonment of operating lease assets (4)		780			—			780			—
Adjusted EBITDA	$	54,570		$	49,368		$	105,592		$	101,233		$	64,654		$	51,022
Revenue													$	203,329		$	160,431
Net income margin (4)														6.0	%		1.0	%
Adjusted EBITDA Margin		30.9	%		40.0	%		31.3	%		39.4	%		31.8	%		31.8	%

(1)

Financing related expenses include third party fees related to proposed financings.

(2)

Acquisition related expenses include third party fees for actual or planned acquisitions, including related legal, consulting and other expenditures, and as applicable, retention bonuses to employees related to acquisitions and change in fair value of contingent consideration.

(3)

~~Non-cash~~Restructuring related expenses include employee severance and other personnel related costs in connection with workforce optimization and organizational changes to ~~equity-based compensation programs, which vary from period to period depending on various factors including the timing, number~~better align with our strategic goals and ~~the valuation of awards.~~future scale.

(4)

Non-cash loss with respect to certain leased office space that was abandoned in the three months ended June 30, 2021. There were no impairment losses in the three and six months ended June 30, 2021 and 2020.

Adjusted EBITDA increased 11% in the three months ended June 30, 2021 to $54.6 million, compared to $49.4 million in three months ended June 30, 2020; and increased 4% in the six months ended June 30, 2021 to $105.6 million, compared to $101.2 million in the six months ended June 30, 2020. This increase was principally a function of the continued growth of our business partially offset by our continued investments in product development and technology, investments in our general and administrative infrastructure as we started operatingNet income margin represents net income as a ~~public company, an increase in sales and marketing spend, and an increase in cost~~percentage of ~~revenue relative to revenue due primarily to offering mix.~~

Adjusted EBITDA Margin was 30.9% in the three months ended June 30, 2021, a decrease from 40.0% in the three months ended June 30, 2020; and 31.3% in the six months ended June 30, 2021, a decrease from 39.4% in the six months ended June 30, 2020. This decrease was primarily due to an increase in marketing spend relative to revenue compared to the second quarter of 2020, in which we proactively reduced our marketing spend at the onset of the COVID-19 pandemic, as well as continued investments in product development and technology, an increase in cost of revenue relative to revenue due to offering mix, and investments in our general and administrative infrastructure.

We expect our Adjusted EBITDA and Adjusted EBITDA Margin to fluctuate primarily based on the level of our investments in sales and marketing and product development and technology relative to changes in revenue.

We generally expect to continue to invest in sales and marketing in the near-term, but will continue to evaluate the impact of COVID-19 on our business and actively manage our sales and marketing spend, including investment in consumer acquisition, which is largely variable, as market conditions change. We also intend to continue to invest in product development and technology to continue to improve our platform, introduce new offerings and scale existing ones. Additionally, we expect to continue to invest in our general and administrative infrastructure to support our operation as a public company.

~~Results of Operations~~

~~The following table sets forth information comparing the components of our results of operations for the periods indicated:~~

Three Months Ended
June 30,

Six Months Ended
June 30,

2021

2020

2021

2020

(in thousands)

Revenue:

Prescription transactions revenue

$
144,857

$
109,548

$
278,918

$
232,565

Subscription revenue

14,316

6,358

26,323

11,998

Other revenue

17,462

7,389

31,825

12,140

Total revenue

176,635

123,295

337,066

256,703

Costs and operating expenses:

Cost of revenue, exclusive of depreciation and amortization presented
separately below

11,090

6,824

21,518

12,843

Product development and technology

29,567

11,962

55,727

22,287

Sales and marketing

88,381

51,920

168,075

115,082

General and administrative

39,579

6,332

83,365

12,219

Depreciation and amortization

8,369

4,521

13,730

8,866

Total costs and operating expenses

176,986

81,559

342,415

171,297

Operating (loss) income

(351
)

41,736

(5,349
)

85,406

Other expense, net:

Other income, net

—

(16
)

—

(21
)
Interest income

(13
)

(41
)

(29
)

(116
)
Interest expense

5,906

6,795

11,811

15,433

Total other expense, net

5,893

6,738

11,782

15,296

(Loss) income before income taxes

(6,244
)

34,998

(17,131
)

70,110

Income tax benefit (expense)

37,305

(7,661
)

49,860

(15,427
)
Net income

$
31,061

$
27,337

$
32,729

$
54,683

Components of our Results of Operations

Revenue

Our revenue is primarily derived from prescription transactions revenue that is generated when pharmacies fill prescriptions for consumers, and from other revenue streams such as our subscription offerings, pharma manufacturer solutions offering, and our telehealth offerings. All of our revenue has been generated in the United States.

•

Prescription transactions revenue: Consists primarily of revenue generated from PBMs, or customer, when a prescription is filled with a GoodRx code provided through our platform. The majority of our contracts with PBMs provide for fees that represent a percentage of the fees that ~~the PBM charges~~PBMs charge to the pharmacy, and a minority of our contracts provide for a fixed fee per transaction. Our percentage of fee contracts often also include a minimum fixed fee per transaction. We expect the revenue contribution from contracts with fixed fee arrangements to remain largely stable over the medium term, and do not expect that changes in revenue contribution from fixed fee versus percentage of fee arrangements will materially impact our revenue. Certain contracts also provide that the amount of fees we receive is based on the volume of prescriptions filled each month.

•

Subscription revenue: Consists of revenue from our Gold and Kroger Savings subscription offerings. ~~Subscription revenue is disclosed separately from other revenue beginning in the second quarter of 2021. Prior period amounts have been recast to conform with the current period presentation.~~

•

~~Other revenue~~Pharma manufacturer solutions revenue: : Consists primarily of revenue generated from pharma manufacturers and other customers for advertising, ~~and~~including integrating onto our platform their affordability solutions to our ~~consumers, advertising in direct mailers, and~~consumers.

•

Other revenue: Consists primarily of revenue generated by our telehealth offerings that allow consumers to access healthcare professionals online.

Beginning in the second quarter of 2021, subscription revenue is disclosed separately from other revenue. Beginning in the first quarter of 2022, pharma manufacturer solutions revenue is disclosed separately from other revenue. Prior period amounts have been recast to conform with the current period presentation.

Costs and Operating Expenses

We incur the following expenses directly related to our cost of revenue and operating expenses:

•

Cost of revenue: Consists primarily of costs related to outsourced consumer support, healthcare provider costs for GoodRx Care, personnel costs including salaries, benefits, bonuses and stock-based compensation expense, for our consumer support employees, hosting and cloud costs, merchant account fees, processing fees and allocated overhead. Cost of revenue is largely driven by the growth of our visitor, subscriber and active consumer base, as well as our ~~revenue~~ offering mix. Our cost of revenue as a percentage of revenue may vary based on the relative growth rates of our various offerings.

•

Product development and technology: Consists primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for employees involved in product development activities, third-party services and contractors related to product development, information technology and software-related costs, and allocated overhead. Product development and technology expenses are primarily driven by increases in headcount required to support and further develop our various products. We capitalize certain qualified costs related to the development of internal-use software, which may also cause product development and technology expenses to vary from period to period. We expect product development and technology expenses will increase on an absolute dollar basis as we continue to grow our platform and product offerings.

•

Sales and marketing: Consists primarily of advertising and marketing expenses for consumer acquisition and retention, as well as personnel costs, including salaries, benefits, bonuses, stock-based compensation expense and sales commissions, for sales and marketing employees, third-party services and contractors, and allocated overhead. Sales and marketing expenses are primarily driven by investments to grow and retain our consumer base and may fluctuate based on the timing of our investments in consumer acquisition and retention. Over the near to medium term, we expect to increase our spending on sales and marketing.

•

General and administrative: Consists primarily of personnel costs including salaries, benefits, bonuses and stock-based compensation expense for our executive, finance, accounting, legal, and human resources functions, as well as professional fees, occupancy costs, other general overhead costs, and as applicable, change in fair value of contingent consideration, and charitable donations. We have incurred, and expect to continue to incur, additional general and administrative costs in compliance, legal, investor relations, insurance, and professional services related to our compliance and reporting obligations as a public company. We have incurred, and also expect to incur, additional general and administrative costs in connection with ~~the vesting~~stock options and ~~settlement of~~ restricted stock units, ~~(“RSUs”),~~ including the ~~grant of restricted stock unit awards covering an aggregate of 12,316,533 shares of Class B common stock to each of our Co-Chief Executive Officers~~Founders Awards made in connection with our ~~IPO (the “Founders Awards”) in particular.~~IPO. We also anticipate that as we continue to grow as a company our general and administrative costs will increase on an absolute dollar basis.

•

Depreciation and amortization: Consists of depreciation of property and equipment and amortization of capitalized internal-use software costs and intangible assets. Our depreciation and amortization changes primarily based on changes in our property and equipment, intangible assets, and capitalized software balances.

Other Expense, Net

Our other expense, net consists of the following:



~~Other income, net:~~ ~~Consists primarily of miscellaneous income that are not core to our operations and, as applicable, third-party transaction expenses related to modifications of our debt facilities.~~

•

Interest income: Consists primarily of interest income earned on excess cash held in interest-bearing accounts.

•

Interest expense: Consists primarily of interest expense associated with ~~the First Lien Credit Agreement (as defined below),~~our debt arrangements, including amortization of debt issuance costs and discounts.

Income Tax (Expense) Benefit ~~(Expense)~~

Our income tax (expense) benefit ~~(expense)~~ consists of federal and state income taxes. We calculate income taxes in interim periods by applying an estimated annual effective income tax rate to (loss) income before income taxes and by calculating the tax effect of discrete items recognized during the period. Our effective income tax rate ~~generally~~ differs from the U.S. federal statutory ~~tax~~ rate of 21.0% primarily due to ~~U.S. federal and state research and development tax credits,~~effects of non-deductible officers’ stock-based compensation expense, state income taxes, research and development tax credits, excess tax benefits from our equity ~~awards.~~awards and changes in the valuation allowance against our net deferred tax assets. For information regarding our calculation of income taxes in interim periods, see Note 6 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Results of Operations

The following table sets forth information comparing the components of our results of operations for the periods indicated:


	Three Months Ended March 31,
(in thousands)	2022			2021
Revenue:
Prescription transactions revenue	$	155,507		$	134,061
Subscription revenue		19,110			12,007
Pharma manufacturer solutions revenue		23,469			9,369
Other revenue		5,243			4,994
Total revenue		203,329			160,431
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below		12,280			10,428
Product development and technology		35,042			26,160
Sales and marketing		92,950			79,694
General and administrative		31,923			43,786
Depreciation and amortization		11,373			5,361
Total costs and operating expenses		183,568			165,429
Operating income (loss)		19,761			(4,998	)
Other expense, net:
Interest income		(52	)		(16	)
Interest expense		5,869			5,905
Total other expense, net		5,817			5,889
Income (loss) before income taxes		13,944			(10,887	)
Income tax (expense) benefit		(1,651	)		12,555
Net income	$	12,293		$	1,668

Three Months Ended ~~June 30, 2021~~March 31, 2022 Compared to Three Months Ended ~~June 30, 2020~~March 31, 2021

Revenue


	Three Months Ended June 30,				Change					Three Months Ended March 31,				Change
	2021		2020		$		%
	(dollars in thousands)
(dollars in thousands)										2022		2021		$		%
Prescription transactions revenue	$	144,857	$	109,548	$	35,309		32	%	$	155,507	$	134,061	$	21,446		16	%
Subscription revenue		14,316		6,358		7,958		125	%		19,110		12,007		7,103		59	%
Pharma manufacturer solutions revenue											23,469		9,369		14,100		150	%
Other revenue		17,462		7,389		10,073		136	%		5,243		4,994		249		5	%
Total revenue	$	176,635	$	123,295	$	53,340		43	%	$	203,329	$	160,431	$	42,898		27	%

Prescription transactions revenue for the three months ended ~~June 30, 2021~~March 31, 2022 increased ~~$35.3~~$21.4 million, or ~~32%~~16%, compared to the three months ended ~~June 30, 2020,~~March 31, 2021, driven primarily by a ~~36%~~12% increase in the number of our average Monthly Active Consumers ~~partially offset by lower contribution-per-consumer due solely to the acquisition of Scriptcycle. Scriptcycle active consumers are included~~. The increase in our prescription transactions revenue and Monthly Active Consumers ~~number beginning~~was primarily driven by organic growth. We believe this organic growth was due to the increase in consumer awareness of our brand as a direct result of the additional investment in sales and marketing expenses on an absolute dollar basis in the ~~fourth quarter~~three months ended March 31, 2022 compared to the three months ended March 31, 2021, which supported new consumer acquisition as well as repeat activity of ~~2020,~~existing consumers. The RxNXT LLC and RxSaver, Inc. acquisitions in July 2021

and April 2021, respectively, individually and in the ~~first full quarter post its acquisition. We believe~~aggregate did not materially contribute to our prescription transactions revenue for the three months ended March 31, 2022.

We believe COVID-19 continues to have an adverse impact on the growth of our prescription transactions revenue, due to the cumulative impact of lower healthcare utilization for approximately two years since the pandemic began. In addition, we recognized that a grocery chain had taken actions late in the first quarter of 2022 that impacted acceptance of discounted pricing for a subset of drugs from PBMs, who are our customers, and whose pricing we promote on our platform. This had an immaterial adverse impact on our prescription transactions revenue in the first quarter and is expected to have an adverse impact on prescription transactions revenue in the future that may be ~~impacted by COVID-19.~~material. Prescription transactions at this grocer represented a material proportion of our prescription volume and revenue during the three months ended March 31, 2022. We are not aware of similar PBM-pharmacy issues at any other large volume pharmacies, and with the exception of the grocer in question, we believe our pharmacy and PBM relationships remain strong. For additional information, please see Part I, Item 1A, “Risk Factors – We rely on a limited number of industry participants.” in our 2021 10-K.

Subscription revenue for the three months ended ~~June 30, 2021~~March 31, 2022 increased ~~$8.0~~$7.1 million, or ~~125%~~59%, compared to the three months ended ~~June 30, 2020,~~March 31, 2021, driven primarily by an increase in the number of ~~subscribers~~subscription plans to ~~1.1~~1.2 million as of ~~June 30, 2021,~~March 31, 2022, compared to ~~0.6~~0.9 million as of ~~June 30, 2020,~~March 31, 2021, as well as a favorable change in subscription plan mix. The increase in subscription revenue was also driven by a pricing increase for a subset of Gold subscribers during the three months ended March 31, 2022, which we expect to rollout for the remaining Gold subscribers by the end of the second quarter of 2022. We expect the increase in Gold pricing to result in slower subscriber growth relative to subscription revenue growth in the near term. We do not believe the grocer issue mentioned above materially impacted subscription revenue in the first quarter of 2022, though it may be impacted in the future.

~~Other~~Pharma manufacturer solutions revenue for the three months ended ~~June 30, 2021~~March 31, 2022 increased ~~$10.1~~$14.1 million, or ~~136%~~150%, compared to the three months ended ~~June 30, 2020. This increase was primarily due~~March 31, 2021, driven by organic growth as we continued to expand our market penetration with pharma manufacturers and other customers, as well as to a lesser extent from the impact of HealthiNation Inc., which we acquired in April 2021.

Other revenue for the three months ended March 31, 2022 increased $0.2 million, or 5%, compared to the three months ended March 31, 2021, driven by an increase in ~~revenue from~~the number of telehealth visits on our ~~pharma manufacturer solutions offering and an increase in telehealth revenue.~~platform.

We expect the percentage growth in subscription and ~~other~~pharma manufacturer solutions revenue to continue to outpace our prescription transactions revenue in the near to medium term as we continue to scale the capabilities and platforms of our subscription and pharma manufacturer solutions ~~and telehealth service~~ offerings.

Costs and Operating Expenses

Cost of ~~Revenue, Exclusive~~revenue, exclusive of ~~Depreciation~~depreciation and ~~Amortization~~amortization


	Three Months Ended June 30,						Change					Three Months Ended March 31,						Change
	2021			2020			$		%
	(dollars in thousands)
(dollars in thousands)												2022			2021			$		%
Cost of revenue, exclusive of depreciation and amortization	$	11,090		$	6,824		$	4,266		63	%	$	12,280		$	10,428		$	1,852		18	%
As a percentage of total revenue		6	%		6	%							6	%		6	%

Cost of revenue for the three months ended ~~June 30, 2021~~March 31, 2022 increased ~~$4.3~~$1.9 million, or ~~63%~~18%, compared to the three months ended ~~June 30, 2020.~~March 31, 2021. This increase was primarily driven by a $1.6 million increase in outsourced and in-house personnel related to consumer support ~~expense~~ to support our ~~growth and a $1.7 million increase in hosting expenses, merchant fees and allocated overhead.~~growth.

Product ~~Development~~development and ~~Technology~~technology


	Three Months Ended June 30,						Change					Three Months Ended March 31,						Change
	2021			2020			$		%
	(dollars in thousands)
(dollars in thousands)												2022			2021			$		%
Product development and technology	$	29,567		$	11,962		$	17,605		147	%	$	35,042		$	26,160		$	8,882		34	%
As a percentage of total revenue		17	%		10	%							17	%		16	%

Product development and technology expenses for ~~the~~ three months ended ~~June 30, 2021~~March 31, 2022 increased by ~~$17.6~~$8.9 million, or ~~147%~~34%, compared to the three months ended ~~June 30, 2020.~~March 31, 2021. This increase was primarily due to increases in ~~product development~~ payroll and related expenses of ~~$13.8~~$6.8 million due to higher headcount and an increase in stock-based compensation expense and payroll taxes related to awards made in connection with and after our IPO. The increase in product development and technology expense was also due to an increase in allocated overhead of ~~$2.2~~$1.4 million in support of our product development efforts.

2420

~~of our product development efforts and an increase in third-party services and contractor expenses related to product development of $1.5 million.~~

Sales and ~~Marketing~~marketing


	Three Months Ended June 30,						Change					Three Months Ended March 31,						Change
	2021			2020			$		%
	(dollars in thousands)
(dollars in thousands)												2022			2021			$		%
Sales and marketing	$	88,381		$	51,920		$	36,461		70	%	$	92,950		$	79,694		$	13,256		17	%
As a percentage of total revenue		50	%		42	%							46	%		50	%

Sales and marketing expenses for the three months ended ~~June 30, 2021~~March 31, 2022 increased by ~~$36.5~~$13.3 million, or ~~70%~~17%, compared to the three months ended ~~June 30, 2020.~~March 31, 2021. This increase was primarily due to a ~~$24.4~~$6.2 million increase in advertising and promotional expenses and a ~~$9.5~~$5.5 million increase in ~~sales and marketing~~ payroll and related expenses due to higher ~~headcount and an increase in stock-based compensation expense and payroll taxes related to awards made in connection with and after our IPO.~~

~~We continue to evaluate the impact of COVID-19 on our business and actively manage our consumer acquisition spending according to market conditions.~~headcount.

General and ~~Administrative~~administrative


	Three Months Ended June 30,						Change					Three Months Ended March 31,						Change
	2021			2020			$		%
	(dollars in thousands)
(dollars in thousands)												2022			2021			$			%
General and administrative	$	39,579		$	6,332		$	33,247		525	%	$	31,923		$	43,786		$	(11,863	)		(27	%)
As a percentage of total revenue		22	%		5	%							16	%		27	%

General and administrative expenses for the three months ended ~~June 30, 2021 increased~~March 31, 2022 decreased by ~~$33.2~~$11.9 million, or ~~525%~~27%, compared to the three months ended ~~June 30, 2020.~~March 31, 2021. This ~~increase~~decrease was primarily due to ~~$24.0~~a $16.1 million ofdecrease in stock-based compensation expense related to the Founders Awards made in connection with ~~the~~our IPO as further described in Note ~~10 of~~11 to our condensed consolidated financial ~~statements. The increase in general and administrative expense was also due to~~statements, partially offset by a ~~$5.9~~$2.1 million increase in ~~other executive and administrative~~ payroll and related expenses due to higher headcount, and ~~an increase in stock-based compensation expense and payroll taxes related to other awards made in connection with and after our IPO, and~~ a ~~$1.9~~$2.1 million increase in ~~acquisition related~~professional and other ~~professional service~~ fees to support our growth and operations as a public ~~company after our IPO.~~company.

Depreciation and ~~Amortization~~amortization


	Three Months Ended June 30,						Change					Three Months Ended March 31,						Change
	2021			2020			$		%
	(dollars in thousands)
(dollars in thousands)												2022			2021			$		%
Depreciation and amortization	$	8,369		$	4,521		$	3,848		85	%	$	11,373		$	5,361		$	6,012		112	%
As a percentage of total revenue		5	%		4	%							6	%		3	%

Depreciation and amortization expenses for the three months ended ~~June 30, 2021~~March 31, 2022 increased by ~~$3.8~~$6.0 million, or ~~85%~~112%, compared to the three months ended ~~June 30, 2020.~~March 31, 2021. This increase was due primarily to a ~~$1.6~~$3.0 million increase in capitalized software amortization due to higher capitalized costs for platform improvements and the introduction of new products and features and a ~~$1.6~~$2.9 million increase in amortization related to acquired intangible assets.

~~Other Income, Net~~

Three Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Other income, net

$
—

$
(16
)

$
16

(100
)%
As a percentage of total revenue

0
%

0
%

~~Other income, net was not material in the three months ended June 30, 2021 and 2020.~~

~~Interest Income~~

Three Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Interest income

$
(13
)

$
(41
)

$
28

(68
)%
As a percentage of total revenue

0
%

0
%

~~Interest income was not material in the three months ended June 30, 2021 and 2020.~~

Interest Expense


	Three Months Ended June 30,						Change						Three Months Ended March 31,						Change
	2021			2020			$			%
	(dollars in thousands)
(dollars in thousands)													2022			2021			$			%
Interest expense	$	5,906		$	6,795		$	(889	)		(13	)%	$	5,869		$	5,905		$	(36	)		(1	%)
As a percentage of total revenue		3	%		6	%								3	%		4	%

Interest expense for the three months ended ~~June 30, 2021~~March 31, 2022 decreased by ~~$0.9 million, or 13%,~~1% compared to the three months ended ~~June 30, 2020~~March 31, 2021 primarily due to lower average debt ~~balances and lower interest rates.~~balances.

Income Tax (Expense) Benefit ~~(Expense)~~


	Three Months Ended June 30,						Change					Three Months Ended March 31,						Change
	2021			2020			$		%
	(dollars in thousands)
Income tax benefit (expense)	$	37,305		$	(7,661	)	$	44,966		(587	)%
(dollars in thousands)												2022			2021			$			%
Income tax (expense) benefit												$	(1,651	)	$	12,555		$	(14,206	)		(113	%)
Effective income tax rate		597.5	%		21.9	%							11.8	%		115.3	%

For the three months ended ~~June 30, 2021,~~March 31, 2022, we had an income tax ~~benefit~~expense of ~~$37.3~~$1.7 million, compared to an income tax ~~expense~~benefit of ~~$7.7~~$12.6 million for the three months ended ~~June 30, 2020~~March 31, 2021 and an effective income tax rate of ~~597.5%~~11.8% and ~~21.9%~~115.3%, respectively. The change in our income tax (expense) benefit ~~(expense)~~ was primarily due to the change from pre-tax income to loss in addition to the tax effects of nondeductible officers’ stock-based compensation expense and excess tax benefits related to our equity awards. The pre-tax loss for the three months ended June 30, 2021 was partially driven by the $24.0 million of stock-based compensation expense related to the Founders Awards made in connection with our IPO.

~~Six Months Ended June 30, 2021 Compared to Six Months Ended June 30, 2020~~

~~Revenue~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Prescription transactions revenue

$
278,918

$
232,565

$
46,353

20
%
Subscription revenue

26,323

11,998

14,325

119
%
Other revenue

31,825

12,140

19,685

162
%
Total revenue

$
337,066

$
256,703

$
80,363

31
%

Prescription transactions revenue for the six months ended June 30, 2021 increased $46.4 million, or 20%, compared to the six months ended June 30, 2020, driven primarily by a 26% increase in the number of our average Monthly Active Consumers, partially offset by lower contribution-per-consumer due solely to the acquisition of Scriptcycle. Scriptcycle active consumers are included in our Monthly Active Consumers number beginningfull valuation allowance recorded in the fourth quarter of ~~2020, the first full quarter post its acquisition. We believe prescription transactions revenue continues to be impacted by COVID-19.~~

~~Subscription revenue for the six months ended June 30,~~ 2021 ~~increased $14.3 million, or 119%, compared to the six months ended June 30, 2020, driven primarily by an increase~~against our net deferred tax assets in ~~the number~~excess of ~~subscribers to 1.1 million as of June 30, 2021, compared to 0.6 million as of June 30, 2020, as well as favorable change in subscription plan mix.~~

Other revenue for the six months ended June 30, 2021 increased $19.7 million, or 162%, compared to the six months ended June 30, 2020. This increase was primarily due to an increase in revenue from our pharma manufacturer solutions offering and an increase in telehealth revenue.

~~We expect the percentage growth in subscription and other revenue to continue to outpace our prescription transactions revenue as~~tax amortizable goodwill, which we ~~continue to scale the capabilities and platforms of our subscription, pharma manufacturer solutions and telehealth service offerings.~~

~~Costs and Operating Expenses~~

~~Cost of Revenue, Exclusive of Depreciation and Amortization~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Cost of revenue, exclusive of depreciation and amortization

$
21,518

$
12,843

$
8,675

68
%
As a percentage of total revenue

6
%

5
%

Cost of revenue for the six months ended June 30, 2021 increased $8.7 million, or 68%, compared to the six months ended June 30, 2020. This increase was primarily driven by a $2.7 million increase in outsourced and in-house personnel related consumer support expense to support our growth, a $1.8 million increase in provider cost related to our telehealth offerings driven by an increase in the number of online provider visits, a $1.4 million increase in hosting expenses, a $1.2 million increase in merchant fees and a $0.8 million increase in allocated overhead.

~~Product Development and Technology~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Product development and technology

$
55,727

$
22,287

$
33,440

150
%
As a percentage of total revenue

17
%

9
%

Product development and technology expenses for the six months ended June 30, 2021 increased by $33.4 million, or 150%, compared to the six months ended June 30, 2020. This increase was primarily due to increases in product development payroll and related expenses of $26.2 million due to higher headcount and an increase in stock-based compensation expense and payroll taxes related to awards made in connection with and after our IPO. The increase in product development and technology expense was also due to an increase in allocated overhead of $3.8 million in support

2721

maintained as of ~~our product development efforts and an increase in third-party services and contractor expenses related~~March 31, 2022. For more information regarding the valuation allowance, see Note 6 to ~~product development of $3.5 million.~~

~~Sales and Marketing~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Sales and marketing

$
168,075

$
115,082

$
52,993

46
%
As a percentage of total revenue

50
%

45
%

Sales and marketing expenses for the six months ended June 30, 2021 increased by $53.0 million, or 46%, compared to the six months ended June 30, 2020. This increase was primarily due to a $30.6 million increase in advertising expenses and a $17.6 million increase in sales and marketing payroll and related expenses due to higher headcount and an increase in stock-based compensation expense and payroll taxes related to awards made in connection with and after our IPO.

~~We continue to evaluate the impact of COVID-19 on our business and actively manage our consumer acquisition spending according to market conditions.~~

~~General and Administrative~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

General and administrative

$
83,365

$
12,219

$
71,146

582
%
As a percentage of total revenue

25
%

5
%

General and administrative expenses for the six months ended June 30, 2021 increased by $71.1 million, or 582%, compared to the six months ended June 30, 2020. This increase was primarily due to $54.0 million of expense related to the Founders Awards made in connection with the IPO as further described in Note 10 of our condensed consolidated financial ~~statements. The increase~~statements appearing elsewhere in general and administrative expense was also due to a $11.4 million increase in other executive and administrative payroll and related expenses due to higher headcount and an increase in stock-based compensation expense and payroll taxes related to other awards made in connection with and after our IPO, and a $4.4 million increase in acquisition related and other professional service fees to support our growth and operations as a public company after our IPO.

~~Depreciation and Amortization~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Depreciation and amortization

$
13,730

$
8,866

$
4,864

55
%
As a percentage of total revenue

4
%

3
%

Depreciation and amortization expenses for the six months ended June 30, 2021 increased by $4.9 million, or 55%, compared to the six months ended June 30, 2020. This increase was due primarily to a $2.8 million increase in capitalized software amortization due to higher capitalized costs for platform improvements and the introduction of new products and

~~features and a $1.5 million increase in depreciation of property and equipment driven by the completion of the build of our new headquarters in Santa Monica, California.~~

~~Other Income, Net~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Other income, net

$
—

$
(21
)

$
21

(100
)%
As a percentage of total revenue

0
%

0
%

~~Other income, net was not material in the six months ended June 30, 2021 and 2020.~~

~~Interest Income~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Interest income

$
(29
)

$
(116
)

$
87

(75
)%
As a percentage of total revenue

0
%

0
%

~~Interest income was not material in the six months ended June 30, 2021 and 2020.~~

~~Interest Expense~~

Six Months Ended
June 30,

Change

2021

2020

$

%

(dollars in thousands)

Interest expense

$
11,811

$
15,433

$
(3,622
)

(23
)%
As a percentage of total revenue

4
%

6
%

Interest expense for the six months ended June 30, 2021 decreased by $3.6 million, or 23%, compared to the six months ended June 30, 2020 primarily due to lower average debt balances and lower interest rates.

~~Income Tax Benefit (Expense)~~

Six Months Ended
June 30,
��

Change

2021

2020

$

%

(dollars in thousands)

Income tax benefit (expense)

$
49,860

$
(15,427
)

$
65,287

(423
)%
Effective income tax rate

291.1
%

22.0
%

For the six months ended June 30, 2021, we had an income tax benefit of $49.9 million, compared to income tax expense of $15.4 million for the six months ended June 30, 2020 and an effective income tax rate of 291.1% and 22.0%, respectively. The change in our income tax benefit (expense) was primarily due to the change from pre-tax income to loss in addition to the tax effects of nondeductible officers’ stock-based compensation expense and excess tax benefits related to our equity awards. The pre-tax loss for the six months ended June 30, 2021 was partially driven by the $54.0 million of stock-based compensation expense related to the Founders Awards made in connection with our IPO.

this Quarterly Report on Form 10-Q.

Liquidity and Capital Resources

~~Overview~~

Since our inception, we have financed our operations primarily through net cash provided by operating activities, equity issuances, and borrowings under our long-term debt arrangements. Our ~~primary requirements for liquidity and capital are to finance working capital, capital expenditures and general corporate purposes. Our~~ principal sources of liquidity are expected to be our cash and cash equivalents and borrowings available under our $100.0 million secured asset-based ~~Revolving Credit Facility.~~revolving credit facility which matures in October 2024. As of ~~June 30, 2021~~March 31, 2022, we had cash and cash equivalents of ~~$894.7~~$845.4 million and ~~$90.9~~$90.8 million available under our ~~Revolving Credit Facility.~~revolving credit facility. For additional information regarding our revolving credit facility and our term loan, refer to Note 7 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. In April 2022 we acquired vitaCare for $150.0 million paid with cash and cash equivalents on hand. Refer to Note 13 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

As of March 31, 2022, there were no material changes to our primary short-term and long-term requirements for liquidity and capital as disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operation” of our 2021 10-K. We believe that our net cash provided by operating activities and cash on hand ~~and availability under our Revolving Credit Facility~~ will be adequate to meet our operating, investing and financing needs for at least the next 12 months. Our future capital requirements will depend on many factors, including our revenue growth, the timing and extent of investments to support such growth, the expansion of sales and marketing activities, and many other factors as described in ~~the section entitled~~Part I, Item 1A, “Risk Factors” of our 2020 10-K and this Quarterly Report on Form 10-Q. We historically have not had any off-balance sheet arrangements nor do we currently have any off-balance sheet arrangements as defined under SEC rules.2021 10-K.

If necessary, we may borrow funds under our ~~Revolving Credit Facility~~revolving credit facility to finance our liquidity requirements, subject to customary borrowing conditions. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all. In particular, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital. If we are unable to raise additional funds when or on the terms desired, our business, financial condition and results of operations could be adversely affected.

In light of the large number of RSUs subject to the Founders Awards that were granted in connection with our IPO in September 2020, we have incurred and anticipate that we will incur substantial additional stock-based compensation expense and expend substantial funds to satisfy tax withholding and remittance obligations as these RSUs vest over time. The grant date fair value of the Founders Awards was $533.3 million. All of the stock price goals with respect to the performance vesting portion of the Founders Awards (the “Performance-Vesting Founders Awards,” see Note 10 of our condensed consolidated financial statements) were achieved in October 2020. As a result, all 16,422,044 Performance-Vesting Founders Awards vested in 2020, and we recognized a total of approximately $373.0 million of stock-based compensation expense related to the Founders Awards during 2020. During the three and six months ended June 30, 2021, we recognized an additional $24.0 million and $54.0 million of stock-based compensation expense, respectively, resulting in a cumulative total of $427.0 million of stock-based compensation expense recognized related to the Founders Awards as of June 30, 2021. The unrecognized stock-based compensation expense associated with the time vesting portion of the Founders Awards of $106.3 million as of June 30, 2021 is expected to be recognized over the weighted average remaining service period of 1.7 years. In addition, as a result of the Founders Awards, and the Performance-Vesting Founders Awards in particular, a large number of shares of Class B common stock will be issued on the applicable settlement dates. On the settlement dates for the RSUs, we plan to withhold shares and remit taxes on behalf of the holders of such Founders Awards at applicable statutory rates, which we refer to as net settlement, which may result in substantial tax withholding obligations. As an employee earns compensation, both the employer and the employee are liable for some portion of Social Security taxes and Medicare taxes (collectively referred to as “FICA” taxes) on the compensation. FICA taxes are generally due in the period when the substantial risk of forfeiture lapses. As the Performance-Vesting Founders Awards vested in October 2020, we accelerated the settlement of 0.7 million RSUs during the fourth quarter of 2020 sufficient to satisfy FICA tax withholding obligations due in the year of vesting. The remaining non-accelerated 15.7 million Performance-Vesting Founders Awards shares will not be issued until October 2023 or, if earlier, a change in control event, as defined in the RSU agreements governing the Founders Awards.

Assuming an approximate 47% tax withholding rate and stock price of $65.00 per share at vesting and settlement, for the 15.7 million Performance-Vesting Founders Award shares that vested as described in the preceding paragraph, we estimate that our cash obligation on behalf of our Co-Founders to the relevant tax authorities to satisfy tax withholding obligations would be approximately $481.7 million, and we would deliver an aggregate of approximately 8.3 million shares of our Class B common stock to net settle these awards, after withholding an aggregate of approximately 7.4 million shares of our Class B common stock. Cash payments for income tax withholdings are due upon the settlement date of the RSUs which is the third anniversary of the applicable vesting date or, if earlier, upon a qualifying change in control event. The actual amount of the tax obligations and the number of shares to be delivered could be higher or lower, depending on the price of our Class A common stock upon settlement and the applicable tax withholding rates then in effect. We also anticipate expending substantial funds to satisfy tax withholding and remittance obligations for other equity awards granted to our employees as they vest over time.

~~First Lien Credit Agreement~~

Our first lien credit agreement (the “First Lien Credit Agreement”) provides for a term loan with an original amount of $700.0 million (the “First Lien Term Loan Facility”). We also have a line of credit with a maximum amount of $100.0 million (the “Revolving Credit Facility”) associated with the First Lien Credit Agreement.

The Revolving Credit Facility and the First Lien Term Loan Facility under the First Lien Credit Agreement are collateralized by substantially all of our assets, including our intellectual property, and 100% of the equity interest of GoodRx, Inc.

The First Lien Credit Agreement that governs the Revolving Credit Facility and the First Lien Term Loan Facility contains certain affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, fundamental changes, repurchases of stock, dividends and other distributions. GoodRx, Inc. is restricted from making dividend payments, loans or advances to GoodRx Intermediate Holdings, LLC and GoodRx Holdings, Inc. In addition, GoodRx, Inc. is subject to a financial covenant whereby GoodRx, Inc. is required to maintain a First Lien Net Leverage Ratio (as defined in the First Lien Credit Agreement) not to exceed 8.2 to 1.0. At June 30, 2021, we were in compliance with the covenants under the First Lien Credit Agreement.

~~Revolving Credit Facility~~

Loans under the Revolving Credit Facility bear interest at a rate per annum equal to the LIBO Screen Rate (as defined in the First Lien Credit Agreement) plus a variable margin rate, which is based on our most recently determined First Lien Net Leverage Ratio (as defined in the First Lien Credit Agreement), that ranges from 2.50% to 3.00%. The Revolving Credit Facility has a variable commitment fee, which is based on our most recently determined First Lien Net Leverage Ratio (as defined in the First Lien Credit Agreement), and ranges from 0.25% to 0.50% per annum. In addition, the Revolving Credit Facility has a fixed fronting fee of 0.125% per annum of our aggregate undrawn and disbursed but unreimbursed letters of credit. The Revolving Credit Facility expires on October 11, 2024. As of June 30, 2021, there was no outstanding principal balance under our Revolving Credit Facility.

Under the terms of a lease agreement entered into during September 2019, GoodRx, Inc. assigned to the landlord drawdown rights against the Revolving Credit Facility for up to $9.0 million to meet the contractual line of credit requirement in the lease agreement. The landlord can draw on the Revolving Credit Facility in the event of our default on rent or damages to the building. The assigned rights to the landlord will be held for the initial three years of the lease term, and subject to certain conditions, the letter of credit will decrease thereafter by up to 10% per year based upon the original amount to no less than $2.0 million. This outstanding letter of credit to the landlord reduces our available borrowings under the Revolving Credit Facility by an amount equal to the value of assigned rights. There were outstanding letters of credit issued against the Revolving Credit Facility for $9.1 million as of June 30, 2021, which reduces our available borrowings under the Revolving Credit Facility to $90.9 million.

~~First Lien Term Loan Facility~~

The First Lien Term Loan Facility accrues interest at a rate per annum equal to the LIBO Screen Rate (as defined in the First Lien Credit Agreement) plus a variable margin rate, which is based on our most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement), that ranges from 2.75% to 3.00% per annum. The First Lien Credit Agreement requires quarterly principal payments through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025.

The effective interest rate on the First Lien Term Loan Facility was 3.39% and 3.83% for the three months ended June 30, 2021 and 2020, respectively and 3.39% and 4.33% for the six months ended June 30, 2021 and 2020, respectively.

~~The carrying value of the First Lien Term Loan Facility was $664.9 million, net of unamortized debt issuance costs and discount of $12.7 million, as of June 30, 2021.~~

Holding Company Status

~~We are~~GoodRx Holdings, Inc. is a holding company that does not conduct any business operations of ~~our~~its own. As a result, ~~we are~~GoodRx Holdings, Inc. is largely dependent upon cash distributions and other transfers from ~~our~~its subsidiaries to meet ~~our~~its obligations and to make future dividend payments, if any. ~~The First Lien Credit Agreement contains~~Our existing debt arrangement contain covenants restricting payments of dividends by our subsidiaries, including GoodRx, Inc., unless certain conditions are met. These covenants provide for certain exceptions for specific types of payments. Based on these restrictions, all of the net assets of GoodRx, Inc. were restricted pursuant to the terms of ~~the First Lien Credit Agreement~~our debt arrangements as of ~~June 30, 2021.~~March 31, 2022. Since the restricted net assets of GoodRx, Inc. and its subsidiaries exceed 25% of our consolidated net assets, in accordance with Regulation S-X, refer to the notes to our ~~audited~~ consolidated financial statements included in our ~~2020~~2021 10-K for condensed parent company financial information of GoodRx Holdings, Inc.

Cash Flows


	Six Months Ended June 30,						Three Months Ended March 31,
	2021			2020
	(in thousands)
(in thousands)							2022			2021
Net cash provided by operating activities	$	80,411		$	83,825		$	30,120		$	45,485
Net cash used in investing activities		(142,416	)		(8,319	)		(34,401	)		(9,695	)
Net cash (used in) provided by financing activities		(14,883	)		25,069
Net cash used in financing activities								(91,401	)		(14,018	)
Net change in cash, cash equivalents and restricted cash	$	(76,888	)	$	100,575		$	(95,682	)	$	21,772

~~Net Cash Provided by Operating Activities~~

Net cash provided by operating activities ~~was $80.4 million for the six months ended June 30, 2021 consisting of $32.7 million~~

Net cash flows provided by operating activities consisted of net income adjusted for ~~$104.9~~certain non-cash items and changes in assets and liabilities. The $15.4 million ~~of non-cash expenses, made up primarily of stock-based compensation of $87.2 million, including $54.0 million of stock-based compensation related~~decrease in net cash provided by operations during the three months ended March 31, 2022 compared to the ~~Founders Awards made in connection with the IPO, partially offset by $57.2~~three months ended March 31, 2021 was due to a $15.3 million ~~of net cash used as a result of~~decrease from changes in operating assets and liabilities. The $10.6 million increase in net income was offset by $10.7 million decrease in non-cash adjustments, primarily driven by a decrease in stock-based compensation expense due principally to the Founders

Awards. The changes in operating assets and liabilities were primarily driven by ~~an increase in income tax receivable due to our second quarter tax benefit~~the timing of payments for accrued expenses and accounts payable as well as ~~increases in accounts receivable due to our growing operations.~~

~~Net cash provided~~ by ~~operating activities was $83.8 million for~~ the ~~six months ended June 30, 2020 consisting~~timing of ~~$54.7 million of net~~ income ~~adjusted for $19.3 million of non-cash expenses~~tax payments and $9.8 million of net cash provided by changes in our operating assets and liabilities. The changes in operating assets and liabilities were primarily driven by increases in accounts receivable, prepaid expenses and other current assets and accrued expenses and other current liabilities due to our growing operations.

~~Net Cash Used in Investing Activities~~refunds.

Net cash used in investing activities ~~of $142.4 million for the six months ended June 30, 2021 was related to $125.7 million~~

Net cash flows used in ~~cash consideration, net~~investing activities primarily consisted of cash ~~acquired, related to~~used for acquisitions ~~$13.6 million for capitalized software~~ and ~~$3.1 million of~~investments, capital expenditures, ~~due primarily to leasehold improvements~~ and ~~furniture and fixtures related to the completion of our new office facility~~software development costs. The $24.7 million increase in Santa Monica, California. In May 2021, we entered into a non-cancelable lease agreement to lease additional space adjacent to our new office facility in Santa Monica, California. We anticipate that we will invest in additional capital expenditures with respect to the expanded leased space principally in 2022, which is the earliest we expect to gain access to and control of the expanded leased property.

~~Net~~net cash used in investing activities ~~of $8.3 million~~ for the ~~six~~three months ended ~~June 30, 2020~~March 31, 2022 compared to the three months ended March 31, 2021 was primarily related to ~~$6.5~~$22.0 million in cash paid for ~~capitalized~~an acquisition of a business and a minority equity interest investment in a privately-held company during the three months ended March 31, 2022, and a $3.7 million increase in software development costs, partially offset by a decrease of $1.0 million in purchases of property and ~~$1.8 million for capital expenditures.~~

~~Net Cash (Used in) Provided by Financing Activities~~equipment.

Net cash used in financing activities

Net cash flows from financing activities primarily consisted of ~~$14.9 million for the six months ended June 30, 2021 was~~payments related to ~~$26.0 million~~our debt arrangements, proceeds from exercise of stock options, payments ~~for employee taxes~~made related to repurchases of our Class A common stock, and payments made related to net share settlement of equity ~~awards, $3.5~~awards. The $77.4 million increase in ~~long-term debt principal payments related to our First Lien Term Loan Facility and $0.8 million payment~~net cash used in financing activities for ~~contingent consideration related~~the three months ended March 31, 2022 compared to the ~~acquisition of Scriptcycle, partially offset by $15.4 million in proceeds from the exercise of stock options.~~

~~Net cash provided by financing activities of $25.1 million for the six~~three months ended ~~June 30, 2020~~March 31, 2021 was primarily related to ~~$28.0~~$83.8 million for repurchases of our Class A common stock during the three months ended March 31, 2022, partially offset by a $1.3 million increase in proceeds from ~~our Revolving Credit Facility, $1.9 million from the exercise~~exercises of stock options ~~partially offset by $3.5~~and a $5.1 million decrease in ~~long-term debt principal~~ payments related to ~~our First Lien Term Loan Facility and payments~~net share settlement of ~~$1.3 million of debt issuance costs related to increasing the amount of our line of credit in May 2020.~~equity awards.

Contractual Obligations and Commitments

~~Other than as described in Note 8 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, there~~There have been no material changes to our contractual obligations and commitments compared with those described in our ~~2020~~2021 10-K.

Critical Accounting Policies and Estimates

During the three months ended ~~June 30, 2021,~~March 31, 2022, there have been no significant changes to our critical accounting policies and estimates compared with those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our ~~2020~~2021 10-K.

Recent Accounting Pronouncements

Refer to Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures ~~about~~About Market Risk

There have been no material changes in our market risk from the disclosure included under “Quantitative and Qualitative Disclosures ofAbout Market Risk” in ~~the 2020~~our 2021 10-K.

Item 4. Controls and Procedures

~~Limitations on Effectiveness of Controls and Procedures~~

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our co-principal executive officers and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, ~~and as a result of the material weaknesses described below,~~ our co-principal executive officers and principal financial officer concluded that, as of ~~June 30, 2021,~~March 31, 2022, our disclosure controls and procedures were ~~not effective at the reasonable assurance level.~~

~~Material Weaknesses~~

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual and interim financial statements will not be detected or prevented on a timely basis.

In connection with the preparation of our consolidated financial statements for 2019, we identified certain control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. The material weaknesses are:



We did not design or maintain an effective control environment commensurate with our financial reporting requirements. We lacked a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally, the limited personnel resulted in an inability to consistently establish appropriate authorities and



~~responsibilities in pursuit of our financial reporting objectives, as demonstrated by, amongst other things, insufficient segregation of duties in our finance and accounting functions.~~



We did not effectively design and maintain controls in response to the risks of material misstatement. Specifically, changes to existing controls or the implementation of new controls have not been sufficient to respond to changes to the risks of material misstatement to financial reporting, due in part to acquisitions and other changes to our business.

~~These material weaknesses contributed to the following additional material weaknesses:~~



~~We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions.~~



We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of business performance reviews, account reconciliations and journal entries. Additionally, we did not design and maintain controls over the classification and presentation of accounts and disclosures in the financial statements.



We did not design and maintain effective controls over certain information technology (“IT”) general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain: (i) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized, and implemented appropriately; (ii) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to certain financial applications, programs and data to appropriate company personnel; (iii) computer operations controls to ensure that critical batch jobs are monitored and data backups are authorized and monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements.

These material weaknesses resulted in adjustments identified by our independent registered public accounting firm and recorded by us primarily related to goodwill, capitalized software, leases, debt extinguishment, revenue recognition and sales allowances. These material weaknesses could result in a misstatement of our accounts or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

~~Remediation Measures~~

We are compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404(a) of Sarbanes-Oxley Act and we are taking steps to remediate the material weaknesses. Management, with the participation of the audit committee and the board of directors, is engaged in remedial activities to address the material weaknesses described above. As of June 30, 2021, substantially all remediation efforts planned to address the material weaknesses have been designed and implemented by management. These implemented controls and procedures are subject to ongoing testing including their operating effectiveness over a sustained period of financial reporting cycles. The finalization of our remediation measures is ongoing and includes the following:



~~We have prepared our remediation plan for each of the material weaknesses and trained process owners, evaluated the design of controls and are monitoring the results of our testing.~~



~~We have engaged third party professionals to advise management in connection with the remediation of each of the material weaknesses including testing the operating effectiveness of controls.~~



We have hired additional accounting, human resources, payroll and IT personnel to bolster our technical reporting, transactional accounting and IT capabilities. We have more than doubled our finance and accounting personnel since the beginning of 2020 through June 30, 2021. We implemented controls to formalize roles and review responsibilities to align with our team’s skills and experience and implemented formal controls over segregation of duties. We continue to evaluate our staffing needs and plan to hire additional resources as necessary to support our operations.



~~We have implemented procedures to identify and evaluate changes in our business and the impact on our controls.~~



We completed the implementation of software solutions in the second quarter of 2021 to support our ability to monitor, assess, and remediate segregation of duties related issues, as well as support our ongoing compliance efforts with Section 404(a) of Sarbanes-Oxley Act.



We have formally assessed, and will continue to formally assess, complex accounting transactions and other technical accounting and financial reporting matters including controls over the preparation and review of accounting memoranda addressing these matters. During the third and fourth quarters of 2020, we implemented controls to identify complex accounting transactions and to require that the accounting implications of such transactions are formally assessed, documented and reviewed by a relevant senior member of our accounting team. In addition, we have engaged third party subject matter experts to advise us with respect to certain complex non-routine transactions in addition to management’s review of such transactions, where appropriate.



Since the beginning of 2020, we implemented several new information systems including a new enterprise resource planning system. We are continuing the process of designing and implementing controls over these systems to, among other things, automate certain controls, enforce segregation of duties and facilitate the review of journal entries.



We have formalized critical accounting policies to achieve complete, accurate and timely financial accounting, reporting and disclosures. Moreover, we have implemented formal processes, policies, and procedures supporting our financial close process, including creating standard balance sheet reconciliation templates, establishing and reviewing thresholds for business performance reviews, and formalized procedures over the review of financial statements. We have implemented an external financial reporting function within our existing finance team to support our regulatory external financial reporting objectives.



We continue to enhance our IT governance processes, including automating components of our change management and logical access processes, enhancing role-based access and logging capabilities, implementing automated controls, enhancing testing and approval controls for program development, and implementing more robust IT policies and procedures over change management and computer operations.

We believe we are making progress toward achieving the effectiveness of our internal control over financial reporting and disclosure controls and procedures. The actions that we are taking are subject to continued testing, ongoing senior management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate these material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness. We may also conclude that additional measures may be required to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional implementation and evaluation time. We will continue to assess the effectiveness of our internal control over financial reporting and take steps to remediate the known material weaknesses expeditiously.effective.

Changes in Internal Control Over Financial Reporting

We are taking actions to remediate the material weaknesses relating to our internal control over financial reporting. Other than the changes to our internal control over financial reporting described in “Remediation Measures” above, thereThere were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended ~~June 30, 2021~~March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3523

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The information required under this Part II, Item 1 is set forth in Note 8 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q and is incorporated herein by this reference.

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in our 2021 10-K. For a discussion of potential risks and uncertainties related to us, see the information included in Part I, Item 1A, "Risk Factors" of our ~~2020~~2021 10-K. ~~There have been no material changes to the risk factors previously disclosed in our 2020 10-K, except as noted below:~~

~~We may experience fluctuations in our tax obligations and effective income tax rate, which could materially and adversely affect our results of operations.~~

We are subject to U.S. federal and state income taxes. Tax laws, regulations and administrative practices in various jurisdictions may be subject to significant change, with or without advance notice, due to economic, political and other conditions, and significant judgment is required in evaluating and estimating our provision and accruals for these taxes. There are many transactions that occur during the ordinary course of business for which the ultimate tax determination is uncertain. Our effective income tax rates could be affected by numerous factors, such as changes in tax, accounting and other laws, regulations, administrative practices, principles and interpretations, the mix and level of earnings in a given taxing jurisdiction or our ownership or capital structures.

On May 28, 2021 the Department of the Treasury released the General Explanation of the Administration's Fiscal Year 2022 Revenue Proposals, also known as the Green Book, outlining a number of proposed amendments to the Internal Revenue Code, including significant changes for corporate taxpayers which includes a proposal to increase the federal corporate tax rate from 21% to 28%. The tax increase legislation is in the early stages of the legislative process and timing of potential tax law changes remain uncertain since the tax increase proposals will need the support of all 50 Democratic Senators. If adopted as proposed, the increase of the corporate tax rate would adversely affect our results of operations in future periods.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds

On September 25, 2020, we completed our IPO. All shares sold were registered pursuant to a registration statement on Form S-1 (File No. 333-248465), as amended (the “Registration Statement”), declared effective by the SEC on September 22, 2020.

There has been no material change in the expected use of the net proceeds from our IPO as described in our Registration Statement. The remaining net proceeds from our IPO have been invested in investment grade, interest-bearing instruments. As of March 31, 2022, we estimate we have used approximately $114.4 million of the net proceeds from our IPO: (i) $34.4 million for the acquisition of businesses that complement our business and (ii) $80.0 million for the repurchases of our Class A common stock.

Issuer Repurchases of Equity Securities

The following table presents information with respect to our repurchases of our Class A common stock during the three months ended March 31, 2022.


							Approximate Dollar
							Value of Shares that
					Total Number of Shares		May Yet Be Repurchased
	Total Number of		Average Price Paid		Repurchased as Part of		Under the Program
Period	Shares Repurchased (1)		per Share (2)		Publicly Announced Program (1)		(in thousands)
January 1 - 31		—	$	—		—	$	—
February 1 - 28		—	$	—		—	$	—
March 1 - 31		5,637,005	$	14.86		5,637,005	$	166,235
Total		5,637,005				5,637,005

(1)

The repurchases are being executed from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. See Note 10 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information related to our stock repurchase program.

(2)

Average price paid per share includes costs associated with the repurchases.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

3625

Item 6. Exhibits

Incorporated by Reference

Filed/

Incorporated by Reference

Filed/

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Furnished

Herewith

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Furnished

Herewith

3.1

Amended and Restated Certificate of Incorporation.

8-K

001-39549

3.1

9/28/20

Amended and Restated Certificate of Incorporation.

8-K

001-39549

3.1

9/28/20

3.2

Amended and Restated Bylaws.

8-K

001-39549

3.2

9/28/20

Amended and Restated Bylaws.

8-K

001-39549

3.2

9/28/20

4.1

Form of Certificate of Class A Common Stock.

S-1/A

333-248465

4.1

9/22/20

Form of Certificate of Class A Common Stock.

S-1/A

333-248465

4.1

9/22/20

4.2

Form of Certificate of Class B Common Stock.

S-8

333-249069

4.4

9/25/20

Form of Certificate of Class B Common Stock.

S-8

333-249069

4.4

9/25/20

10.1^

First Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated August 14, 2020.

10.1

Third Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated March 18, 2022.

10.2^

Second Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated May 27, 2021.

10.2^+

Stock Purchase Agreement, dated as of March 6, 2022, by and between GoodRx, Inc. and TherapeuticsMD, Inc.

31.1

Certification of Co-Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).

31.2

Certification of Co-Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).

31.3

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).

32.1

Certification of Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2

Certification of Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.3

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

** Furnished herewith.

^ Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is treated as confidential by us.

+ The annexes, schedules, and certain exhibits to this ~~exhibit~~Exhibit have been omitted pursuant to Item ~~601(b)(10)(iv)~~601(a)(5)(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	GOODRX HOLDINGS, INC.

Date: May 9, 2022	By:	/s/ Douglas Hirsch
		Douglas Hirsch
		Co-Chief Executive Officer
		(principal executive officer)

Date: ~~August 12, 2021~~May 9, 2022	By:	/s/ ~~Douglas Hirsch~~Trevor Bezdek
		~~Douglas Hirsch~~Trevor Bezdek
		Co-Chief Executive Officer
		(~~Principal Executive Officer)~~principal executive officer)

Date: ~~August 12, 2021~~May 9, 2022	By:	/s/ ~~Trevor Bezdek~~Karsten Voermann
		~~Trevor Bezdek~~Karsten Voermann
		~~Co-Chief Executive~~Chief Financial Officer
		(~~Principal Executive Officer)~~principal financial officer)

Date: ~~August 12, 2021~~May 9, 2022	By:	/s/ ~~Karsten Voermann~~Romin Nabiey
		~~Karsten Voermann~~Romin Nabiey
		Chief ~~Financial~~Accounting Officer
		(~~Principal Financial and Accounting Officer)~~principal accounting officer)

3827


	Six Months Ended June 30,					��	Change
	2021			2020			$		%
	(dollars in thousands)
Income tax benefit (expense)	$	49,860		$	(15,427	)	$	65,287		(423	)%
Effective income tax rate		291.1	%		22.0	%